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ABSTRACT 
Recovery of the P53 tumor suppressor pathway via small molecule inhibitors of onco-
protein MDM2 highlights the critical role of computational methodologies in targeted 
cancer therapies. Molecular docking programs in particular, provide a quantitative 
ranking of predicted binding geometries based on binding free energy allowing for the 
screening of large chemical libraries in search of lead compounds for cancer therapeutics. 
This study found improved binding mode predictions of medicinal compounds to MDM2 
using the popular docking programs AutoDock and AutoDock Vina, while adopting a 
rigid-ligand/flexible-receptor protocol.  Crystal structures representing small molecule 
inhibitors bound to MDM2 were selected and a total of 12 rotatable bonds was supplied 
to each complex and distributed systematically between the ligand and binding site 
residues. Docking results were evaluated in terms of the top ranked binding free energy 
and corresponding RMSD values from the experimentally known binding site. Results 
show lowest RMSD values coincide with a rigid ligand, while the protein retained the 
majority of flexibility. This study suggests the future implementation of a rigid-
ligand/flexible-receptor protocol may improve accuracy of high throughput screenings of 
potential cancer drugs targeting the MDM2 protein, while maintaining manageable 
computational costs. 
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INTRODUCTION 
 
 
Molecular Docking: A Computational Methodology Aiding Drug Discovery 
            Our increasing understanding of bio-molecular binding processes has been aided 
by computational docking programs, which utilize physics-based free energy functions 
and search algorithms to predict the likely covalent and non-covalent binding sites of 
small molecules to macromolecules, such as proteins, DNA and RNA, based on the 
quantitative ranking of the binding free energy [1]. This methodology has become 
especially relevant in the field of structure-based drug design (SBDD), which uses the 
known 3D structure of target molecules to design small medicinal compounds as 
therapeutics [2]. This small molecule referred to as a ligand, is often an inhibitor to some 
function of the target molecule and must be designed to firmly bind at a specific location 
on the selected target macromolecule (figure 1) [3]. Consequently, docking programs 
have become an essential tool in the research and design of cancer therapeutics as they 
allow the quick and accurate screening of drug candidates early in the drug discovery 
pipeline, thereby precluding a large investment in time and money [4]. The virtual 
screening of small molecules from chemical libraries attempts to manage the vast 
chemical space of all possible compounds available to be optimized as future cancer 
drugs [5]. These large high throughput screenings (HTS) are able to exclude or include 
available compounds in silico, as drug leads based on desired binding geometry; often 
referred to as “binding pose” or “binding mode”, and binding affinity, which is 
determined by the binding free energy [6]. Due to the complexity inherent in simulating 
the dynamics of the molecular binding process, docking programs introduced a time-
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independent strategy based on chemical potentials rather than the force calculations 
associated with classical molecular dynamics (MD), which use time dependent 
Newtonian physics [7][8]. Docking programs use energy evaluations based on 
assumptions, estimates and empirical knowledge while estimating, rather than 
calculating, binding free energy [9].  Cancer therapeutic research such as targeting onco-
proteins relies on a critical understanding of ligand-protein binding and is subject to the 
effectiveness of computational techniques such as molecular docking [10]. Therefore, 
Particular attention to understanding the limitations and efficacy of these programs will 
ensure proper use and enable further modifications.  
 
                                         
 
Overview of AutoDock and AutoDock Vina 
            Currently, there are over 50 docking programs in use worldwide [11]. AutoDock, 
Figure 1. Molecular docking predicts the preferred location and binding affinity of 
small molecules to proteins, DNA and RNA from an unbound configuration. Taken 
from [103]. 
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introduced in 1990, is an often cited, freely available program maintained by the Scripps 
Research Institute [12]. Its widespread use can be attributed to its free availability to 
academic users as well as its versatility and accuracy. AutoDock was the first program to 
model ligand flexibility, and with the release of AutoDock 4, has incorporated protein 
side-chain flexibility [13][14]. Although significant advances in this and other programs 
have been made in the last 25 years, AutoDock suffers from many of the same limitations 
as other docking programs. In fact, the number of programs reflects these limitations, as 
it signifies an inability to converge on one scoring function and one search method that 
would be applicable for a variety of ligand-protein, protein-protein, ligand-DNA or 
protein-DNA interactions [1][15][16]. Due to its wide use in commercial and academic 
environments, AutoDock has been the focus of validation studies, which have highlighted 
efficiencies and certain limitations. For example, AutoDock has been shown to be 
accurate for ligands with 6 or less rotatable bonds within 2 angstroms of the 
experimentally known 3D structure, but as the ligands’ rotatable bonds increase, 
performance decreases, and is not reliable after 10 [17][10]. This problem arises from the 
exponential increase in conformational space that must be evaluated for every additional 
rotatable bond. This restriction has been the most notable difficulty pertaining to protein-
ligand docking and has led to a rigid receptor as the standard methodology because of the 
computational challenges posed by the numerous degrees of freedom involved in 
incorporating protein residue flexibility [18]. This lack of allowed flexibility fails to 
address the proteins’ conformational changes during binding. The accurate, 
computational simulation of protein conformational changes is critical to improved 
docking studies because it accounts for changes affecting the final binding geometry [19]. 
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It has been shown that, when only a rigid receptor conformation is considered, docking 
studies predict incorrect binding poses for about 50–70% of all ligands [20].  In response, 
AutoDock introduced a feature that allowed the incorporation of protein flexibility, which 
is intended to account for a portion of the conformational changes of the protein upon 
binding. However, the flexibility of the protein and more importantly, the binding site 
residues are still subject to the limits imposed by the number of rotatable bonds; 
therefore, this feature is limited to the ligand and protein having a total of about 10 
rotatable bonds.  
            AutoDock Vina, a faster, more accurate alternative, was released in 2010. 
(henceforth referred to as Vina). This program was able to improve accuracy, while 
drastically reducing computation time through effective computer architecture and 
adopting a “machine learning” approach for the scoring function [21]. Vina was tested 
using the same complexes evaluated during the development of AutoDock 4 and results 
show a marked improvement in terms of ligand binding mode accuracy and 
computational time as compared to AutoDock 4 (figure 2). Vina’s combination of speed 
and accuracy has made it an ideal program for HTS and has been used in several research 
studies and novel docking approaches [22][23]. Although AutoDock 4 and Vina share 
similarities in the use of an empirically weighted scoring function and global search 
optimization algorithm, they differ in their local search strategy and global and scoring 
function parameters [21].  
 
Improving Binding Mode Predictions 
            As aforementioned, the two most significant results from a docking experiment 
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include the binding free energy of a particular bound complex and the ligand binding 
mode prediction. The focus of this research is improving the ligand binding mode 
predictions of AutoDock and Vina through selective flexibility of the ligand and receptor 
by invoking AutoDock’s feature of protein residue flexibility, while utilizing the speed 
and accuracy of Vina to reduce computational time. Few studies have highlighted 
AutoDock’s protein flexibility feature, and no study has been found regarding results 
from adjusting ligand flexibility, which is another feature available to users. For this 
study, four structures, all representing small medicinal compounds in complex with the 
onco-protein MDM2 (murine double minute 2), were selected from the Protein Data 
Bank (PDB). Docking experiments were performed using all structures with AutoDock 
and Vina employing the standard protocol. This was followed by docking runs applying a 
Figure 2. Percentage of the 190 test complexes AutoDock and AutoDock Vina were 
able to predict within 2 Å of the experimentally known binding site. Taken from [21]. 
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systematic transfer of flexibility from the ligand to protein for determining the optimal 
configuration of flexibility to produce the best binding mode prediction. Analysis of these 
results was supplemented by classical MD simulations performed by the Nanoscale 
Molecular Dynamics program (NAMD) [24]. MD simulation programs, such as NAMD, 
utilize classical Newtonian physics to study the time dependent structure, dynamics, and 
thermodynamics of biological molecules. The microscopic properties of atomic positions 
and velocities can be translated into macroscopic quantities such as temperature, pressure 
and volume using statistical mechanics. This enables the determination of the movement 
associated with the flexible binding site residues of the target protein most associated 
with the binding interactions [8].  
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TARGETED MEDICINE AND CANCER 
 
The Cost of Cancer 
            Cancer is among the leading causes of death worldwide. In 2012, there were 14 
million new cases and a reported 8.2 million cancer-related deaths.  In 2015, an estimated 
1,658,370 new cases of cancer will be diagnosed in the United States and 589,430 people 
will die from the disease [25]. Pharmaceutical companies are estimated to spend an 
average of 2.5 billion dollars per every new drug that comes to market because nearly 
95% of new drugs tested on humans fail to be effective and safe (figure 3) [26]. A 2012 
article in Nature Reviews Drug Discovery reports the number of drugs invented per 
 
 
Figure 3. Drug companies spend billions of dollars on developing new drugs, and as this 
amount rises each year, the cost of Cancer therapeutics and other drugs will continue to 
rise to offset their investment. Drug companies must spend billions of dollars for each 
new drug developed that will most likely fail. Taken from [104]. 
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billion dollars of research and development invested has been cut in half every nine years 
over the past 50 years. In many cases, drug companies spend millions of dollars over the 
course of several years before the drugs are proven to be ineffective. This enormous 
investment and large failure rate drives drug costs higher as companies try to recoup their 
investment when a small amount of medications are successful [27][26]. Drug companies 
have initiated strategies to lower costs such as abandoning projects earlier that show low 
probable success rate, partnering with other companies to reduce costs, and targeting rare 
diseases because they can be more lucrative as the cost per patient is higher [28]. Also, 
the U.S government has taken steps to help reduce costs by eliminating red tape 
attempting to fast track drugs to market. In 2014, the Food and Drug Administration 
(FDA) approved 41 drugs that had not been approved previously for any indication, the 
most in nearly 20 years. Of these 41 novel drugs, 9 were approved for the treatment of 
cancer or cancer-related conditions [29].  
 
Targeted Medicine 
            Over the past ten years, the development of targeted cancer therapies has 
overtaken standard chemotherapy treatments. Targeted cancer therapies are drugs or 
other substances that block the growth and spread of cancer by interfering with 
specific molecules that aide or promote the growth and spread of cancer cells [30]. This 
strategy reduces toxicity, because unlike chemotherapies, which are chosen for their 
ability to kill cells, both cancerous and healthy, targeted drugs are designed only to act 
upon relevant cancerous molecules. These targeted therapies have proved successful as 
two thirds of cancer patients, most of whom are recipients of such therapies, survive 5 
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years after diagnosis [31]. However, despite the recent successes and improved diagnosis 
for cancer patients, targeted therapeutics are more expensive and suffer from certain side-
effects and limitations. For example, these drugs mostly target proteins in the cancer cell 
whose biological function is not reserved for just one activity, and often the function 
targeted by the small molecule inhibitor is modulated by other proteins. Often the cell 
will create a new pathway, bypassing the protein the inhibitor was affecting, In other 
words, the cell acquires a resistance and unfortunately, it can happen quickly [32]. 
Improved understanding of these molecular pathways has led to the identification of the 
mechanisms of acquired resistance, which can be mitigated with novel inhibitors. 
Improving targeted cancer treatments in the future will require expanding our knowledge 
of resistance mechanisms toward the development of new rationally designed novel 
inhibitors and translating this information to the clinic to select patients for appropriate 
therapy [33].  
            In addition to resistance, another complication associated with targeted drug 
therapies is off-site binding. This occurs when inhibitors bind to proteins other than the 
intended target resulting in the unintended disruption of molecular pathways leading to 
detrimental side-effects. This has become the norm rather than the exception [34]. 
Research into the extent of drug promiscuity has shown on average each drug binds to 6.3 
protein receptors. In fact, the complexity and resiliency of biological systems has led to 
the failure of most single target, single drug approaches [35]. The problem of off-site 
binding contributes to the 95% fail rate, as this many times is only discovered in phase 1 
or 2 clinical trials [36]. The interactions associated with off-site binding is now being 
used as a strategy known as polypharmacology, which focuses on searching for drugs that 
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bind to multiple targets to modify disease associated pathways instead of targeting one 
protein using a single ligand [34]. This addresses the cells ability to circumvent the 
modification of certain proteins targeted by small inhibitors, which leads to resistance 
and continued cancer growth. In 2012, a drug called regorafenib was approved to treat 
colorectal cancer by blocking six different cancer pathways [37]. Despite this recent 
success, employing this strategy is a daunting challenge because the effects of binding for 
the entire biological system must be realized, as well as determining the proper structure 
of the small molecule to induce high infinity binding. The binding affinity of a ligand to a 
protein is based on the chemical structure of the ligand and the ligand binding propensity 
of the protein, and even a weak binding to multiple targets can affect the biological 
system [38].  
 
Computer-Aided Structure-Based Drug Design 
            SBDD utilizes the known 3D structure of a target molecule realized through 
nuclear magnetic resonance spectroscopy, homology modeling or the most common 
technique, X-ray crystallography, to elucidate the structural components of proteins and 
ligand-protein complexes [9]. The high resolution associated with these techniques 
allows for the determination of atomic interactions within the target protein and within 
small compounds that may be used to bind to the target protein. This allows researchers 
to locate and focus on a particular area of medicinal interest on the target molecule, while 
invoking computational methodologies such as docking and MD [39]. This computer-
aided approach of SBDD is essential for accurate determination of lead compounds 
through the virtual screening of chemical libraries early in the drug discovery pipeline as 
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there are now over one million small molecules in data bases available as possible drug 
candidates (figure 4) [40].         
            The structure-based virtual screening procedure performed by docking programs 
have been used since the early 1980’s, tasked with exploring the possible binding modes 
and binding affinity of a ligand within a known target area. The target area is a specific 
location on the protein surface active in the modulation or functionality of that protein 
[41].  Most often, the introduction of a small medicinal compound is used to disrupt 
oncogenic protein function, rather than attempting to restore a cancerous cell to a healthy 
one [42].  For example, in healthy cells, the MDM2 protein binds to the tumor suppressor 
protein P53, marking it for degradation when it has become obsolete after its brief six-
minute lifetime. This binding initiates a signaling pathway, alerting other proteins, called 
ubiquitin, to disassemble P53. In cancerous cells, MDM2 is over expressed, leading to 
reduced levels of P53. The P53 binding pocket of MDM2 is a medicinal target because it 
provides an opportunity to block this interaction, which is critical to the levels of these 
tumor suppression proteins found in cancerous cells [43] . In addition, docking programs 
perform virtual screenings targeting DNA with small molecule intercalates and minor 
groove binders designed to disrupt cancerous cell replication leading to cell death [42]. 
            Virtual screenings begin with foreknowledge of a binding target area based on a 
crystallized structure already developed. The docking results of the tested ligands can 
then be compared to the experimentally known structure based on position and binding 
affinity. Location and position, along with binding free energy, are the two key factors in 
determining a successful docking [3]. The binding affinity is a measure of the estimated 
energy evaluations based on different molecular interactions. This prediction reflects the 
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strength of the non-covalent physical binding between the two molecules [9]. Due to the 
reliance on estimates and assumptions inherent in the free energy calculations, the 
binding free energies are generally viewed as un-reliable as a true measure of the free 
energy. Even when a particular binding mode can be determined, the binding affinity is in 
doubt due to the complex interactions estimated by the semi-empirical scoring functions 
often employed by docking programs using simplified free energy models. The problem 
arises when the experimentally determined binding free energies determined from 
dissociation constants are quantitatively different from the estimates used for docking 
Figure 4. Use of computer-aided drug design in the search for a candidate drug is a 
time consuming, costly endeavor utilizing numerous methodologies and techniques. 
Taken from [105].  
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experiments [44]. However, docking methodologies in SBDD are still widely used as 
they provide a complimentary technique for the discovery and optimization of lead 
compounds for future cancer drugs. The most common applications of computer 
methodologies in the drug discovery process are as follows: 
1. Due to the large number of small molecules that need to be evaluated, virtual 
high throughput screenings (VHTS) can include or exclude possible candidates 
based on the desired binding criteria. This process saves time and money 
compared to traditionally screenings. The most likely candidates can then be 
optimized and evaluated more precisely using more expensive methods such as 
MD simulations [6]. 
 
 2.  When lead compounds are identified, further optimization can be guided by the 
            structure based knowledge from the crystallized complex. MD simulations can be 
     applied to measuring binding free energy and elucidating pharmacological effects, 
     such as absorption, distribution, metabolism, excretion, and the potential for  
     toxicity (ADMET). In addition, quantitative structure-activity relationships 
            (QSAR) analysis is used to reveal the relationship between structure and activity 
           and the relevant molecular parameters [6] [45].  
 
3. Computer techniques allow researchers to build molecules from the ground up, in 
    a process called de novo design, by piecing together functional groups or 
    fragments to design novel compounds. Pharmacophore modeling, a technique that 
    defines the critical features of small compounds that initiate bioactivity with a 
    larger macromolecule, is used to develop different designs that produce the same 
    medicinal outcome [6]. 
 
Due to the concurrent emergence of targeted medicine, structure based screening and 
computer technology, the role of computer aided drug design (CADD) has become an 
intense focus of medicinal chemistry. In particular, molecular docking programs and 
classical MD have been used extensively as a preliminary tool for the detection and 
optimization of small molecules purposed as cancer drugs [46]. Future breakthroughs in 
cancer treatments will almost certainly rely on improvements related to these 
methodologies. 
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     THE ROLE OF P53 AND MDM2 IN CANCER THERAPEUTICS 
 
Introduction 
            P53 is a tumor suppressor protein found in the nucleus of cells, which functions to 
respond to cellular stress by mediating cell-cycle arrest, senescence or apoptosis in 
response to DNA damage, oncogene activation, and hypoxia [47]. P53 is one of the most 
important proteins found in eukaryotic cells because the proper functioning of p53 is 
critical to tumor suppression. This protein is called “guardian of the genome”, because it 
responds to cell damage by blocking cell division and inducing cell death, thereby 
stopping malignant cancerous cell division. Inactivation of the p53 pathway is found in 
the majority of human cancers. In almost 50% of cancers, the TP53 gene that encodes 
p53 is inactivated through mutation or deletion [48]. In much of the other 50%, 
functionality of p53 is lost or compromised due to cellular regulatory mechanisms that 
have been damaged due to cellular stress. In healthy cells, p53 levels are kept low and 
have a half-life of 6 to 20 minutes, but this half-life doubles as p53 levels increase to 
promote cell repair through its transcription activity [49]. In 7% of cancers, p53 levels are 
degraded due to the over expression of the regulatory protein MDM2, which functions as 
an E3 ubiquitin ligase responsible for the ubiquitination and degradation of p53 (figure5) 
[50] . This 7% represents a sample of 28 different types of human cancers from almost 
4,000 human tumor samples [51]. The over expression of MDM2 is the result of gene 
amplification mediated by p53. In this way, p53 and MDM2 form an auto-regulatory 
feedback loop [52]. When this pathway is disabled due to cell damage, the DNA 
damaged cells may proliferate resulting in the formation of tumors [52][50]. Since                                          
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Figure 5. a) P53 activates the production of MDM2. b) MDM2 binding to P53 
initiates the degradation of P53 via the ubiquitin system. c) Phosphorylation of P53 
at Ser15, Thr18 or Ser20 will interrupt binding with MDM2. These three residues are 
not phosphorylated in normal cells keeping P53 at low levels by MDM2. d) DNA 
damage may facilitate the activation of protein kinase to phosphorylate P53 at one of 
the three residues causing an increase in P53 levels. Due to MDM2 expression being 
activated by P53, the increase of P53 also increases MDM2, but this has no effect 
when P53 is phosphorylated. When the DNA damage is repaired, the kinase is no 
longer active and P53 will quickly be dephosphorylated and have levels reduced by 
the accumulated MDM2. Taken from [106]. 
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MDM2 affects other cellular processes not associated with p53, and various cellular 
molecules contribute to regulate the pathway, the full oncogenic role of MDM2 is not 
fully understood. Studies have shown increased levels of MDM2 may contribute to 
cancer formation independent of its role as a regulator of p53 [53]. However, there is 
considerable evidence that increased levels of MDM2 lead to accelerated tumor growth in 
many types of cancers and in particular those cancers coinciding with low levels of p53 
in damaged cells, which has led the p53/MDM2 pathway to become a focus point for 
cancer therapeutics [54]. In particular, the targeting of the post translational nature of the 
p53/MDM2 interaction, which can initiate an immediate response towards lowering 
MDM2 levels [53].  
 
The P53/MDM2 Binding Structure 
            The binding of MDM2 to p53 is well understood and the biochemical structure of 
this complex has been established by examining the crystallographic data resulting from 
the resolved crystal structure. MDM2 binds to a 15 amino acid amphipathic peptide at the 
NH2 terminus of p53, while the MDM2 binding domain is found in a small hydrophobic 
pocket located at its NH2 terminus containing residues 25-109 [55]. This binding 
mediates gene transactivation of p53 through a non-covalent physical binding which 
blocks the p53 transactional domain. A second and more salient result for our discussion 
is this binding also marks the protein for degradation by the proteasome, which is a 
protein designed to break the peptide bonds holding proteins together [56][57][58]. This 
the mechanism by which p53 levels are lowered and tumor growth is allowed to progress.             
Chemotherapies attempt to recover the tumor suppression activity of p53 by introducing 
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small non-peptide molecules into cancerous cells that mimic the critical residues, Phe 19, 
Trp23 and Leu26, associated with the p53 binding pocket of MDM2. Levels of p53 
should increase given that small molecules can be designed to bind to MDM2 in these 
critical domains before the ubiquitination process occurs [55]. The fortuitous nature of 
the structure of MDM2 has been exploited in the development of such small molecules. 
Human MDM2 is a 491- amino acid long phosphoprotein, whose p53 binding domain is 
found in a well-defined hydrophobic surface pocket encompassing a relatively small area 
of the protein. The binding pocket measures only 18 Å along the long edge; the size of a 
typical small molecule [59]. The MDM2 cleft is formed by amino acids 26–108, and 
consists of two structurally similar portions that fold up into a deep groove lined by 14 
hydrophobic and aromatic residues [55][60].  
 
Small Molecule Inhibitors of MDM2 
 
            The physical and chemical structure of MDM2 has enabled many small molecule 
inhibitors, such as nutlins, spiroxindoles and isolindones, and chalcone derivatives, to be 
designed from lead compounds discovered via the experimental and computational 
screening of large chemical libraries (figure 6) [60]. Pharmacological optimization can 
then be carried out to produce the desired physicochemical properties, such as essential 
high binding affinities and high specificity over other proteins. The nutlins were the first 
group of optimized small molecule inhibitors discovered at Hoffmann-La Roche in 2004 
and advanced to phase 1 clinical trials in 2012, and a second generation of inhibitors has 
been designed with greater potency and improved selectivity, which are currently in 
phase 1 clinical trials [61]. Results from the first trial, using an optimized nutlin 
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compound administered to 20 patients, have been mixed. The drug known as RG7112, 
was administered to patients with lipsarcoma, a form of malignancy of fat cells. The post 
Figure 6. Small molecule inhibitors must be designed to firmly attach to the P53 
binding site of MDM2 in order to block binding and subsequent degradation of 
tumor suppressor P53 in damaged cells. Knowledge and simulation of binding site 
residues shown in green, enable accurate predictions by docking programs and 
lead to a more efficient drug discovery pipeline. The efficient utilization and future 
optimization of these programs are essential for hastening drug discovery and 
reducing costs of therapeutic development. This illustration was produced using 
Chimera software during this research. 
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clinical data showed while some tumors were kept from growing; only one was reduced 
and several patients showed toxicity in the form of thrombocytopenia, a condition in 
which your immune system attacks your own platelets. However, although most of the 
focus has been to develop drugs targeting the p53/MDM2 pathway, a new class of 
MDM2 inhibitors has been developed for cancers that have no functional p53, including 
pancreatic, prostate, and advanced breast cancer. These drugs bind directly to MDM2 
promoting self-degradation and inhibiting transcription in a p53 independent and MDM2 
dependent manner [62][63].  
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COMPUTATIONAL METHODOLOGIES AIDING STRUCTURE BASED 
 
 DRUG DESIGN 
 
 
 
Molecular Docking 
 
            The computational evaluation of bio-molecular interactions is a challenging task, 
responsible for the development of over 50 programs dedicated to predicting the likely 
location and binding affinity of small molecules to macro-molecule receptors, such as 
DNA, RNA and proteins. The two principle components of these programs include 
conformational search methods and binding free energy evaluations. In practice, a 
balance must be struck between computational cost and accuracy, for medicinal 
chemistry, this trade-off becomes increasingly important, as thousands of compounds can 
be tested focusing on one macromolecule target [3]. Considering the receptor and ligand 
each possess six degrees of translational and rotational freedom as well as conformational 
degrees of freedom, there exists a tremendous number of possible binding modes. In an 
attempt to manage this complexity, molecular docking programs utilize various 
conformational search strategies and scoring functions (figure 7) [64]. 
            Conformational Search Strategies. The first docking programs developed in the 
early 1980’s used a simplified model of ligand-protein interaction called “lock and key” 
theory, which held both the ligand and receptor rigid. Later, the “induced fit” theory 
stated that the active site of the protein is continually reshaped by interactions with the 
ligand, and accounting for this movement would increase the accuracy of binding mode 
predictions [65]. However, as stated earlier, this is a daunting computational challenge 
and has led to the use of a flexible ligand-rigid receptor protocol, which still remains the  
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most popular method in use [20]. Using this protocol reduces the amount of possible 
binding orientations thereby reducing computational time and cost. Contemporary 
docking programs have adopted various sampling algorithms to survey the user defined 
conformational binding space. 
            The two methods most commonly used can be classified as systematic and 
Figure 7. The two main facets of a molecular docking program are the search method 
and scoring function. Different methods are used for both and have been adopted by 
50 different docking programs throughout the world. This chart reflects the flow of the 
most important aspects of these programs culminating in evaluation of the RMSD 
from the either known experimental site or targeted location. Molecular docking 
represents an early evaluation and precedes more expensive time consuming 
evaluations and trials. Taken from [107]. 
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stochastic [66]. Both apply an incremental change to the structural parameters of the 
ligand, including the torsional, translational and rotational degrees of freedom. The 
systematic approach methodically changes the structural orientation of the ligand, thereby 
inducing different conformational states and binding modes [67]. The binding energies 
are calculated for each docking during numerous evaluation cycles in search of the 
ligand-protein orientation producing the lowest binding free energy and therefore, the 
most likely binding mode [68] . This structural manipulation attempts to simulate the 
changes to the ligand facilitated by its interaction with the protein [69][67]. This method 
is conducive to a thorough exploration of the search space, but is subject to settling on a 
local, rather than global energy minimum. It also encounters a combinatorial explosion 
due to all the possible ligand orientations [66]. To counter this, an incremental algorithm 
is employed to evaluate fragments of the ligand separately as they are placed within the 
either desired, or suspected protein binding site. A fragment is selected and evaluated 
until the binding mode corresponding to the minimum energy is realized, than another 
fragment is added, and the process is repeated until the entire ligand is constructed and 
evaluated ending in a final binding orientation with minimum binding energy [66][9].  
            The Conformational space can also be surveyed through Stochastic methods by 
randomly modifying a ligand conformation or a population of ligands. Monte Carlo (MC) 
and genetic algorithms (GA) are typical algorithms representing this technique. The basic 
MC search has the ligand perform a random sampling of different locations around the 
protein. At each location, the ligand orientation is randomly altered and then evaluated in 
terms of acceptance criteria. If the energy is lower than the previous step, it proceeds 
from that orientation. If the energy is higher or the same, a probabilistic approach is used 
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to dictate the most advantageous adjustment. This will continue until a user defined 
number of conformations is gathered in search of the global minimum energy. A 
modification of this technique is simulated annealing MC. After a defined number of 
steps, the system temperature is lowered, producing conformations less likely to have 
increased energy, thereby moving the system toward energy minima [70] [9].  
            Similar to MC, the GA also adopts a randomness approach, which is based on 
Darwin’s theory of evolution and natural selection [71][72]. First, the structural 
parameters of the ligand are translated or encoded into a chromosome. From this 
chromosome, which actually represents the pose of the ligand, the search algorithm 
randomly produces a population of chromosomes representing a substantial portion of the 
energy landscape. This population’s fitness is evaluated and the most adapted 
chromosomes, or those with the lowest energy values, are selected as templates to 
parturitate the next population. Then, mutation makes random alterations to the genes, 
such as crossover exchanging of genes between two chromosomes, producing a new 
ligand pose with new structural parameters. This cyclic process reduces the  
average energy of the chromosome ensemble by transferring an optimal set of values 
describing the translational, orientation, and conformation of the ligand as it binds to the 
protein, thereby reducing the conformational space to be explored [73][72]. The search 
performed by the GA is iterative, and after a large, yet manageable number of cycles, 
converges on a conformation corresponding to the global energy minimum [66]. The 
main advantage of the GA and MC strategies is their ability to sample a large amount, 
rather than all of the possible binding orientations in a reasonable amount of time, while 
still locating the minimum binding energy. In contrast, the systematic approach aided by 
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incremental procedures searches all possible conformational space, making it less 
practical for larger ligands. 
            Energy Evaluations. Although scoring functions used in molecular docking for 
determining the binding free energy are still considered inaccurate, docking programs 
provide a guide to the realization of pharmaceuticals based on the cost effective 
evaluation of drug candidates [16][2]. This can be accomplished without an exact 
determination of the binding free energy by establishing binding location and orientation 
before more expensive, time consuming techniques are utilized such as linear activation 
energy (LAE) and free-energy perturbation methods (FEP) [74]. Given current 
computing speeds, a more robust, accurate scoring function would be impractical due to 
the computational time necessitated by each small molecule being screened. Again, this is 
due to the combinatorial explosion of conformational states accompanied by degrees of 
freedom issued to the ligand or protein. In addition, properly accounting for surrounding 
water molecules and ions would further add to the computational costs. This would 
eliminate the cost and time benefit allotted by in silico techniques. Hence, the scoring 
functions adopted by docking programs provide a trade-off between time and accuracy 
via best estimates and assumptions of binding interactions using implicit solvent and 
fixed entropic contributions [15]. The most basic assumption is molecules will seek the 
most stable binding orientation characterized by a deep potential energy well indicated by 
the amount of energy released upon binding. The energy functions attempt to estimate 
this energy and therefore, the most likely binding mode. The scoring functions most 
commonly used to estimate binding affinity are classified into force-field based,  
empirical based and knowledge-based scoring functions (figure 8) [1][6].  
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            Force-field based scoring methods utilize chemical potentials to calculate binding 
energy by summing the non-bonded, distant-dependent, atomic pairwise van der Waals 
and electrostatic interactions. The van der Waals terms are calculated from a Lennard-
Jones potential function. This distance-dependent function can be adjusted by setting 
different parameters for the Lennard-Jones potential such as controlling how close a 
contact between protein and ligand atoms will be accepted as contributing to the total 
energy. Therefore, reducing this distance will lead to diminished accuracy of long-range 
effects contributing to binding. Additional terms are often added to these scoring 
Figure 8. Scoring functions are divided into three main categories although many, such 
as AutoDock, may incorporate different features of each. AutoDock uses force-field 
based calculations and empirical quantities during energy evaluations. 
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functions considering hydrogen bonding, solvation and entropy contributions as well 
[9][66][7]. The particular scoring function employed by a docking program varies by the 
terms used and the values adopted by empirical testing when installing the hydrogen, 
solvation, and entropy terms. Therefore, the values attributed to these terms will depend 
on the test set selected for calibration. A large set of diverse ligand-receptor complexes 
including ligand-protein, ligand-DNA, protein-protein and ligand-RNA will be more 
applicable, but less accurate, while only selecting for instance, ligand-protein complexes 
will be accurate, but less adaptable [75]. The advantage of force-field based scoring 
functions is that they provide the most realistic model of binding interactions with 
acceptable computational costs. The problem is their inaccuracy in estimating entropic 
contributions. This limitation is due to the lack of a reasonable physical model to describe 
this phenomenon. Furthermore, the solvent is not explicitly considered, hindering the 
estimation of desolvation energies [66].     
            A popular form of the force-field based potentials is currently used with the 
AMBER molecular dynamics software package and has been adopted for use in docking 
programs. The AMBER force fields are represented by: 
 
                 𝐸𝑎𝑚𝑏𝑒𝑟 =  𝐸𝑎𝑛𝑔𝑙𝑒 + 𝐸𝑏𝑜𝑛𝑑 + 𝐸𝑑𝑖ℎ𝑒𝑑𝑟𝑎𝑙 + 𝐸𝑛𝑜𝑛−𝑏𝑜𝑛𝑑𝑒𝑑             (1)
 
                  
 
     
                 
 
Eangle and Ebond  are harmonic approximations of the bond angle and strain energies, 
respectively, and Edihedral  is an energy term associated with the dihedral angles of 
linearly-bonded sets of four atoms. The term Enon-bonded  aggregates the non-bonded 
interactions: a Lennard-Jones 6-12 potential which approximates the van der Waals 
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attraction, and Pauli repulsion, and an electrostatic potential term. The ff94 force field, 
which uses the AMBER functional form, has been very popular for simulating proteins. 
Also, subsequent versions including AMBER 99SB force field and the general AMBER 
force field (GAFF) contain parameters suitable for modeling the interactions of small 
organic molecules associated with drug design [15]. 
            Empirical scoring functions use a simplified calculation that allows for high-speed 
computation for virtual database screening. Empirical functions provide efficient 
performance for groups of proteins or compounds that are similar to complexes within 
the training set, but performance decreases when applied to different protein families 
[66]. The foundation of empirical scoring functions is based on structural features and is 
often guided by physical interactions. However, these functions are not derived from first 
principles, but are directly calibrated with a set of protein-ligand complexes with 
experimentally determined structures and binding affinities based on multiple linear 
regression analysis or machine learning methods in an attempt to measure the favorability 
of an interaction rather than fully elucidate the underlying physics of the event. It is a 
simplified approach, attempting to save computational time, while accurately predicting 
binding interactions [76]. The terms in the master equation represent a particular physical 
process involved in the formation of a ligand-receptor complex. The functions combine 
features such as hydrophobic contacts, hydrophilic contacts, number of rotatable bonds or 
number of hydrogen bonds, and parameterize these features using a diverse training set of 
ligand-receptor complexes. This establishes the coefficients of the scoring function which 
is multiplied by each component and summed to produce a final score [77]. 
            Knowledge-based scoring functions use pairwise energy potentials taken from 
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known ligand-receptor complexes to create a general function. These potentials are 
developed by accounting for the frequency two distinct atoms are found within a given 
distance in the structural dataset based on the assumption that more favorable interactions 
occur with greater frequency. The frequency distributions are then converted into 
pairwise atom-type potentials. The different types of interactions observed in the dataset 
are classified and weighted according to their frequency of occurrence and the sum of 
these individual interactions is given by the final docking score [66][78]. The inverse-
Boltzmann equation provides the relationship between the frequency of features and the 
energy that is assigned to those features. For protein-ligand interactions, the energy 
assigned to the interaction between ligand atom type i and protein atom type j, at a 
distance of  𝑟𝑘 (the distance of the k
th bin), can be computed as follows: 
 
                               𝑈𝜌𝑚𝑓,𝑖𝑗(𝑟𝑘) =  −𝑘𝐵𝑇 ln [
𝜌𝑖𝑗(𝑟𝑘) 
𝜌𝑖𝑗,𝑟𝑒𝑓
]                                       (2) 
       
                                   
The quantity  (𝜌𝑖𝑗(𝑟𝑘) )/𝜌𝑖𝑗, 𝑟𝑒𝑓)  is the relative radial density for atom pair type ij 
within the training set and is a function of the bond distance 𝑟𝑘. The density 𝜌𝑖𝑗,𝑟𝑒𝑓   
associated with the reference state may be computed using an ideal gas approximation or 
other approaches. Since knowledge-based functions are not reliant on the calculation of 
binding affinities as with force-field methods, nor do they attempt to reproduce binding 
affinities, as with empirical functions, they offer a good balance between accuracy and 
speed. They also perform well with ligand-receptor complexes outside their structural 
dataset [15]. 
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AutoDock             
            Scoring Function. AutoDock 4 employs a semi-empirical free energy force field 
based on a linear regression analysis and the amber force field described in the previous 
section. The force field parameters were chosen from using a large number of protein-
inhibitor complexes for which both structure and inhibition constants, or Ki , are known. 
Improvements installed in this newest version allows for the incorporation of protein side 
chain flexibility due to the calculation of bound and unbound inter and intra-molecular 
energies (figure 9) [14]. The total binding free energy is the difference between the 
unbound states of the ligand and protein and the total bound energy of the complex. Most 
simply, the energy of the ligand and protein separately is always greater than the bound 
complex, the difference is the binding free energy, it is always negative, and determines 
the depth of the energy well and the amount of energy needed to break apart the complex 
[7]. These calculations are augmented by a second program called Autogrid, which 
performs pre-calculations of binding affinity’s and stores this information for the actual 
docking run. Autogrid works with AutoDock and must be implemented before all 
docking runs. The force field evaluates binding in two steps, while the protein and ligand 
begin in an unbound conformation. First, the intramolecular energetics are estimated for 
the transition from these unbound states to the conformation of the ligand and protein in 
the bound state. Then, the free energy function evaluates intermolecular energetics of 
combining the ligand and protein in their bound conformation: 
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Figure 9. The force field used by AutoDock evaluates binding in two steps. The 
first step evaluates the energetics of the ligand and protein separately by 
determining the intramolecular energies, which is the energy within the ligand or 
protein rather than between the two, associated with the transition from the 
unbound state to the bound state they will adopt when they form the complex. 
Then, the second step evaluates the intermolecular energies, or the energy 
between the ligand and protein associated with the binding. The difference 
between the unbound and bound energies represents the binding free energy. It is 
the energy released during the formation of the complex in an attempt by the 
ligand and protein to reach the lowest energy possible. Molecules will settle in a 
location and geometry with the lowest possible negative binding energy to ensure 
a secure conformation. Docking programs use this tendency to evaluate this 
energy and determine likely binding geometries. Taken from [7]. 
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 𝐺 = (𝑉𝑏𝑜𝑢𝛥𝑛𝑑
𝐿−𝐿 −  𝑉𝑢𝑛𝑏𝑜𝑢𝑛𝑑
𝐿−𝐿 ) + (𝑉𝑏𝑜𝑢𝑛𝑑
𝑃−𝑃 − 𝑉𝑏𝑜𝑢𝑛𝑑
𝑃−𝑃 ) + (𝑉𝑏𝑜𝑢𝑛𝑑
𝑃−𝐿 )                     (3)    
 
 
The force field includes six pair-wise evaluations (V) and includes a term for the 
conformational entropy lost upon binding, ∆Sconf. Where ‘L’ and ‘P’ refer to the ligand 
and protein. The terms included in the first two parentheses calculate the intramolecular 
energies for the bound and unbound states of the protein and ligand separately. The third 
parentheses estimates the intermolecular energy from the bound and unbound state. The 
total conformational entropy lost upon binding is calculated by multiplying a constant 
(W) by the total number of rotatable bonds (N). The default constant used for AutoDock 
4 is .314 Kcal/mol. 
 
                                                         𝛥𝑠𝑐𝑜𝑛𝑓 = 𝑊𝑐𝑜𝑛𝑓 𝑁𝑡𝑜𝑟                                                                  (4)
 
 
 Each pair-wise energy evaluation includes terms for dispersion/repulsion, hydrogen 
 bonding, electrostatics and desolvation (figure 10): 
 
ΔG = 𝑊𝑣𝑑𝑤 ∑ (
𝐴𝑖𝑗
𝑟𝑖𝑗
12 − 
𝐵𝑖𝑗
𝑟𝑖𝑗
6 )
𝑖𝑗
+ 𝑊ℎ𝑏𝑜𝑛𝑑  ∑ 𝐸(𝑡) (
𝐶𝑖𝑗
𝑟𝑖𝑗
12 −
𝐷𝑖𝑗
𝑟𝑖𝑗
10
𝑖𝑗
) +  𝑊𝑒𝑙𝑒𝑐 ∑   
𝑞𝑖  𝑞𝑗
𝜀(𝑟𝑖𝑗)𝑟𝑖𝑗𝑖𝑗
+ 𝑊𝑠𝑜𝑙  ∑ (𝑆𝑖𝑉𝑗 +  𝑆𝑗𝑉𝑖 exp (
−𝑟𝑖𝑗
2
2𝜎2
))
𝑖𝑗
                                                           (5) 
 
All terms are preceded by a weighting constant (W) determined by a set of empirically 
determined binding constants. The summations are calculated for all pairs of ligand 
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atoms, i, and protein atoms, j, as well as all pairs of atoms comprising the ligand 
separated by three or more bonds. The first term is a 6/12 potential representing 
dispersion/repulsion interactions. The second, is a directional H-bond term based on a 
10/12 potential. The parameters C and D provide a well depth of 5 kcal/mol at 1.9Å for 
hydrogen bonds with oxygen and nitrogen, and a well depth of 1 kcal/mol at 2.5Å for 
hydrogen bonds with sulfur. The function E (t) provides directionality based on the angle 
from ideal H-bonding geometry. The third term is a screened Coulomb potential for 
electrostatics. The desolvation potential is based on the volume of atoms (V) that 
surround a given atom weighted by a solvation parameter (S) and an exponential term 
with distance-weighting factor σ=3.5Å. AutoDock4 introduced an improved desolvation 
model that includes terms for more atom types. The atomic solvation parameter (Si) is a 
function of the atomic charge (qi): 
 
                                                                  𝑆𝑖 = (𝐴𝑆𝑃𝑖 + 𝑄𝐴𝑆𝑃 ×  |𝑞𝑖|)                                                      (6) 
 
Where ASPi is the atomic solvation parameter of atom i and QASP is the charged-based 
atomic solvation parameter (QASP = 0.01097, stderror = 0.0063) [7][79]. 
            Autogrid. AutoGrid is a program responsible for the pre-calculation of grid maps 
reflecting the interaction energies for various atom types, such as aliphatic carbons, 
aromatic carbons, hydrogen bonding oxygens, and so on, with a macromolecule such as a 
protein, DNA or RNA. Autogrid also produces an electrostatics potential map and a 
desolvation map [79]. A probe atom from each atom type of the ligand is placed at 
different points on a grid designated by the user as for the size and spacing. The energy of 
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interaction of this single atom with the protein is assigned to the grid point. The default 
spacing for AutoDock is .375 Ǻ, which is about a quarter of the length of a carbon-carbon 
bond [79]. The maximum grid box size is 126 points in each direction. The distance 
between each point correlates to one grid spacing which can be increased up to 1 Ǻ when 
creating the grid box. These grid maps are then used by AutoDock to determine the total 
interaction energy for a ligand when docked with a macromolecule. This pre-calculation 
AutoDock 4.1 Forcefield 
Interatomic Distance (Angstroms) 
Figure 10. Interatomic forces used for the AutoDock force field. These terms are 
used together with weighting constants which are optimized based on 
experimentally characterized complexes. This reduces computation time, but also 
reduces accuracy of the binding free energy calculation. Taken from [7]. 
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of the atomic affinity potentials for each atom type performed by Autogrid saves time 
during the docking because the non-bonded interactions are stored and used during the 
calculation. Also, what was a calculation with order N-squared complexity, is reduced to 
one that is order N, where N is the number of atoms interacting [13]. 
            Protein Side-Chain Flexibility. AutoDock 4 allows for flexibility of protein 
residue rotamers to reflect, at least to a small extent, conformational changes of the 
protein when binding with a ligand (figure 11). Accounting for protein conformational 
changes has long been a goal of molecular docking programs for accurate binding 
predictions [80][81]. There have long been reported examples of differences in the 
proteins bound and un-bound state ranging from local side-chain rearrangements, to 
large-scale conformational changes, such as domain motions, hinge bending motions, or 
un-folding of entire segments [82]. Although different strategies have been designed to 
reflect protein flexibility including soft docking, selective docking, ensemble docking, 
four dimensional docking, on-the-fly docking, hybrid docking, and composite structure 
docking, AutoDock side-chain flexibility is treated explicitly to simulate the induced fit 
mechanism of the side-chain residues as the ligand enters the binding site. This technique 
is suitable for side-chain residues and is not applicable for reflecting substantial protein 
changes associated with protein domain movements [83]. Due to the exponential increase 
in search space for each rotatable bond granted to the ligand or protein, only a small 
number of bonds can be selected in addition to the ligands rotatable bonds before the 
added search space prevents convergence on a local minima. Those residues most related 
with binding interactions and that are not embedded within the protein are ideal for 
flexibility (figure 12). Binding site residue information is usually available from the 
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crystallographic data associated with the complex. Visualization software, such as 
Chimera, visual molecular dynamics (VMD) or AutoDock tools (ADT), just to mention a 
few, can provide further insight into the binding site interface. 
            Conformational Search Method. AutoDock provides a choice of search 
methods including simulated annealing and a genetic algorithm without a local search, 
but for most applications, the Lamarckian Genetic Algorithm (LGA) produces the best 
results. An initial population of conformations is established and then mutated during the 
course of successive generations. Future generations inherent conformational parameters, 
and those “individuals” possessing local minima binding free energy, pass these “traits” 
to the next generation, mimicking evolutionary natural selection. The LGA search 
method involves several steps. Initially, all the variables and evaluations are defined. The 
binding geometry of a ligand and a protein is defined by values representing the 
translation, orientation, and conformation of the ligand with respect to the protein. These 
values are the ligands state variables and each corresponds to a gene. The ligand’s state 
corresponds to the genotype and its atomic coordinates correspond to the phenotype. A 
genotype is described by one chromosome. The chromosome is composed of a string of 
real valued genes: three Cartesian coordinates for the ligand translation; four variables 
defining a quaternion specifying the ligand orientation; and one real–value for each 
ligand torsion. In evolutionary terms, the fitness of an individual determines which traits 
are advanced to the next generation. The fitness variable in the LGA is the total 
interaction energy of the ligand with the protein, and is evaluated using the free energy 
function. Random individuals are mated using a process of crossover, where each new 
individual inherits genes from either parent. Also, some offspring mutate randomly when 
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one gene changes by a random amount [71].  
            After each generation, a local search is performed using a defined portion of the 
population with an algorithm developed by Solis and Wets, which surveys the genotypic 
space rather than the phenotypic space. This explicit local search allows 
Figure 11. AutoDock uses the same method to model flexibility in both the 
ligand and side-chain residue. A root atom for the ligand can either be 
chosen by the user or the AutoDock tools module when preparing the ligand 
for docking. The atom linking the amino acid to the protein, which will 
remain in a fixed position during the simulation, is included as the root for 
protein flexibility and is selected by AutoDock tools automatically when 
preparing the flexible residue file. Flexibility in the case of the ligand and 
protein only refers to rotation, the bond angles and bond lengths remain 
fixed. Taken from [79]. 
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BEGIN_RES ARG A 364 
REMARK  4 active torsions: 
REMARK  status: ('A' for Active; 'I' for Inactive) 
REMARK    1  A    between atoms: CA   and  CB   
REMARK    2  A    between atoms: CB   and  CG   
REMARK    3  A    between atoms: CG   and  CD   
REMARK    4  A    between atoms: CD   and  NE   
REMARK       I    between atoms: NE   and  CZ   
REMARK       I    between atoms: CZ   and  NH1  
REMARK       I    between atoms: CZ   and  NH2  
ROOT 
ATOM      1  CA  ARG A 364      15.543  -3.599  11.058  1.00 20.66     0.176 C  
ENDROOT 
BRANCH   1   2 
ATOM      2  CB  ARG A 364      14.218  -2.825  10.902  1.00 23.02     0.036 C  
BRANCH   2   3 
ATOM      3  CG  ARG A 364      13.215  -3.537   9.968  1.00 25.74     0.023 C  
BRANCH   3   4 
ATOM      4  CD  ARG A 364      11.968  -2.720   9.626  1.00 29.66     0.138 C  
BRANCH   4   5 
ATOM      5  NE  ARG A 364      10.929  -2.819  10.645  1.00 32.22    -0.227 N  
ATOM      6  HE  ARG A 364      11.111  -2.383  11.537  1.00  0.00     0.177 HD 
ATOM      7  CZ  ARG A 364       9.757  -3.440  10.493  1.00 31.86     0.665 C  
ATOM      8  NH1 ARG A 364     9.435  -4.047   9.353  1.00 31.44    -0.235 N  
ATOM      9  NH2 ARG A 364     8.886  -3.427  11.490  1.00 29.11    -0.235 N  
ATOM     10 1HH1 ARG A 364    8.538  -4.501   9.259  1.00  0.00     0.174 HD 
ATOM     11 2HH1 ARG A 364    10.088  -4.054   8.582  1.00  0.00     0.174 HD 
ATOM     12 2HH2 ARG A 364     9.116  -2.960  12.356  1.00  0.00     0.174 HD 
ATOM     13 1HH2 ARG A 364       7.991  -3.884  11.385  1.00  0.00     0.174 HD 
ENDBRANCH   4   5 
END_RES ARG A 364 
 
 
 
Figure 12. Example of AutoDock’s flexible residue file describing parameters for 
flexible protein residues. This file is separate from both the ligand and rigid portion 
of the protein so that each residue can be modeled explicitly. The user decides the 
bonds made active (A). All other bonds within the selected residue will remain rigid 
(I).  The maximum number of rotatable bonds is 32, but results begin to decline after 
10 depending on the structure. Vina has reported success with up to 20 rotatable 
bonds in terms of RMSD values. The Root Atom labeled ‘CA’ is a carbon atom 
connecting the amino acid to the residue ARG364.  
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for the inclusion of small, refined changes without the need for switching from the 
genotypic space to the phenotypic space as is the case for most algorithms. This local 
search method enables individual conformations to search their local conformational 
space, finding local minima, and then pass these parameters to later generations. The 
individual’s fitness determined by the binding free energy will determine survival to the 
next generation [71]. As with all computational methodologies, a balance must be struck 
between an exhaustive calculation and computational cost. Although a rigorous searching 
algorithm would go through all possible binding modes between the two molecules, this 
search would be impractical due to the size of the search space and amount of time it 
might take to complete. As a consequence, only a small amount of the total 
conformational space can be sampled. Theoretically, given enough computational power 
and time, every possible rotational and translational orientation of the ligand relative to 
the protein could be explored. 
 
AutoDock Vina 
            Scoring Function.  The developers of Vina adopted a machine learning approach 
instead of using a traditional physics-based scoring function. The general functional form 
of the conformation-dependent part of the scoring function Vina is designed to work with 
is: 
                                            𝑐 =  ∑ 𝑓𝑡𝑖𝑡𝑗  (𝑟𝑖𝑗)𝑖<𝑗                                                        (7) 
 
where the summation is over all of the pairs of atoms that can move relative to each 
other, normally excluding atoms separated by 3 consecutive covalent bonds. Here, each 
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atom i is assigned a type tj and a symmetric set of interaction functions f𝑡𝑖  f𝑡𝑗 of the 
interatomic distance rij should be defined. This value can be seen as a sum of 
intermolecular and intramolecular contributions: 
 
                                             𝑐 =  𝑐𝑖𝑛𝑡𝑒𝑟 +  𝑐𝑖𝑛𝑡𝑟𝑎                                                              (8) 
 
The optimization algorithm is tasked with finding and ranking the global minimum 
of c and additional low-scoring conformations. The predicted binding free energy is 
calculated from the intermolecular portion of the lowest-scoring conformation, 
designated as 1: 
 
                                   𝑠1 = 𝑔(𝑐1 −  𝑐𝑖𝑛𝑡𝑟𝑎1) = 𝑔(𝑐𝑖𝑛𝑡𝑒𝑟1)                                        (9) 
 
where the function g can be an arbitrary strictly increasing smooth possibly nonlinear 
function. In the output, other low-scoring conformations are also formally given s values, 
but, to preserve the ranking, using 𝑐𝑖𝑛𝑡𝑟𝑎of the best binding mode: 
 
                                                𝑠𝑖 = 𝑔(𝑐𝑖𝑛𝑡𝑟𝑎1)                                                                (10) 
 
For modularity reasons, much of the program does not rely on any particular functional 
form of f𝑡𝑖𝑡𝑗  interactions or g. Basically, these functions are passed as a parameter for the 
rest of the code. Also, this program is designed so that alternative atom typing schemes 
could be used, such as the AutoDock 4 atom typing. The AutoDock Vina scoring 
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function is a combination of knowledge-based potentials and empirical scoring functions, 
which uses information from both the conformational preferences of the receptor-ligand 
complexes and known affinity measurements. The interaction functions f𝑡𝑖𝑡𝑗  are defined 
relative to the surface distance, 
                                              
                                              dij = rij − R𝑡𝑖− R𝑡𝑗                                                       (11) 
 
Where Rt is the van der Waals radius of atom type t and h𝑡𝑖𝑡𝑗  is a weighted sum of  
                             
                                           𝑓𝑡𝑖𝑡𝑗 (𝑟𝑖𝑗) ≡  ℎ𝑡𝑖𝑡𝑗(𝑑𝑖𝑗)                                                  (12) 
 
steric interactions identical for all atom pairs, hydrophobic interaction between 
hydrophobic atoms, and, where applicable, hydrogen bonding. The hydrophobic term 
equals 1, when d < 0.5Å; and 0, when d > 1.5Å, and is linearly interpolated between 
these values. The hydrogen bonding term equals 1, when d < −0.7Å; and 0, when d > 0, 
and is similarly linearly interpolated in between. In this implementation, all interaction 
functions f𝑡𝑖𝑡𝑗  are cut off at rij = 8Å. The conformation-independent function g was 
chosen to be: 
 
                                           𝑔(𝑐𝑖𝑛𝑡𝑒𝑟) =  
𝑐𝑖𝑛𝑡𝑒𝑟
1+𝑤𝑁𝑟𝑜𝑡
                                                     (13) 
 
where Nrot is the number of active rotatable bonds between heavy atoms in the ligand, 
and w is the associated weight. The speed and accuracy of Vina was tested using the 
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same 190 receptor-ligand training set sampled by AutoDock 4. Results showed a two 
orders of magnitude improvement in speed and significant improvement of binding mode 
predictions. Vina can achieve near-ideal speed-up by utilizing multiple CPU cores 
through multithreading (figures 13 and 14). Most computer code is serialized, resulting in 
tasks performed by the program to be carried out in a sequential manner, one after 
another. The multithreaded architecture divides tasks and runs them concurrently, leading 
to a substantial decrease in computation time [21]. 
            Conformational Search Method. The search method used by Vina is an iterated 
local search global optimizer. In this algorithm, a succession of steps consisting of a 
mutation and a local optimization are taken, with each step being accepted according to 
the Metropolis criterion. Local optimization is carried out using the Broyden-Fletcher-
Goldfarb-Shanno (BFGS) method, which is a quasi-Newton method. BFGS uses the 
value of the scoring function, in addition to its gradient, by taking the derivatives of the 
value of the scoring function with respect to its arguments. These arguments are the 
position and orientation of the ligand, in addition to the values of the torsions for the 
active rotatable bonds in the ligand and flexible residues, if any. These derivatives would 
have a simple mechanical interpretation, if the scoring function were an energy. The 
derivatives with respect to the position, orientation and torsions would be the negative 
total force acting on the ligand, the negative total torque and the negative torque 
projections, respectively, where the projections refer to the torque applied to the branch 
“moved” by the torsion, projected on its rotation axis. While it may take longer to 
evaluate the gradient in addition to the value of the scoring function, using the gradient 
can speed up the optimization significantly. Several runs starting from random 
 42 
 
 
 
            
 
conformations are performed. These runs can be performed concurrently using the 
multithreading computer strategy built into Vina resulting in substantially reduced 
Figure 13. Contrast between single and multi-threaded computer architecture. Taken from 
[108]. 
 
Figure 14. Vina has achieved a drastic reduction in computation time along with 
improved accuracy. Taken from [21]. 
minutes 
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computational time. The optimization algorithm maintains a set of diverse significant 
minima found that are then combined from the separate runs and used during the 
structure refinement and clustering stage [21]. 
 
Molecular Dynamics 
            In addition to molecular docking, MD simulations have become an essential 
computational tool used in the drug design process. In contrast to docking experiments, 
MD simulations are time dependent. This allows for understanding the dynamic behavior 
of proteins at different timescales, from fast internal motions to slow conformational 
changes or even protein folding processes. It is also possible to study the effect of explicit 
solvent molecules on protein structure and stability to obtain time-averaged properties of 
the biomolecular system, such as density, conductivity, and dipolar moment, as well as 
different thermodynamic parameters, including interactions energies and entropies [46]. 
Although MD is often used as an umbrella term, there are two related forms of this 
technique. In the classical mechanics approach to MD simulations, molecules are treated 
as classical objects, resembling very much the ‘ball and stick’ model. Atoms correspond 
to soft balls and elastic sticks correspond to bonds. The dynamics of the system using this 
technique is governed by classical mechanics and Newtonian physics. The quantum or 
‘first-principles’ MD simulations, take explicitly into account the quantum nature of the 
chemical bond. The electron density function for the valence electrons that determine 
bonding in the system is computed using quantum equations, whereas the dynamics of 
ions (nuclei with their inner electrons) is followed classically. This strategy provides a 
detailed, quantum mechanical insight toward a number of biological systems, but is 
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impractical for systems with thousands of atoms with timescales of processes as long as a 
nano-second [84]. The precise calculations of quantum methods are applicable to smaller 
more defined systems. 
            MD simulations use the iterative numerical calculation of instantaneous forces 
present in a system and the subsequent movements in that system (figure 15). The system 
consists of a set of particles that move in response to their interactions according to the 
equations of motion defined in classical Newtonian mechanics. As with molecular 
docking, classical MD is much more efficient than might be expected from full 
consideration of the physics of biomolecular systems due to the number of substantial 
approximations. Most notably, each atom is treated as a point mass. This approximation 
is justified in terms of the Born-Oppenheimer approximation, which states only the 
nuclear displacements need to be considered while ignoring the electronic configuration 
[8] . With this assumption, Newton’s second law can be used and the calculation becomes 
deterministic in nature. Knowing the starting positions and velocities of the atoms allows 
us to apply Newton’s second law and determine the future or past state of the system.  
The mathematical description of this method is as follows: 
     
                                                    𝐹𝑖 =  𝑚𝑖𝑎𝑖                                                                   (14) 
 
where 𝐹𝑖 is the force exerted on particle i, 𝑚𝑖   is the mass of particle i, and 𝑎𝑖  is the 
acceleration of particle i. The net force, 𝐹𝑖, exerted on the atom i by the remainder of 
the system is given by the negative gradient of the potential-energy function with 
respect to the position of atom i, 
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                                                            𝐹𝑖 =  −
𝑑𝑉
𝑑𝑟𝑖
                                                             (15)  
 
 
 
The Newtonian equation of motion for atom i is, 
 
                                               
𝑑𝑝𝑖  
𝑑𝑡
=  𝐹𝑖                                                   (16)  
                                                                     
Given the position with respect to a single component of vector 𝑟𝑖, at a specific time, t, 
then the position after a short and finite interval, denoted Δt, is given by a standard 
Taylor series: 
                        𝑥(𝑡 +  𝛥𝑡) = 𝑥(𝑡) +
𝑑𝑥(𝑡) 
𝑑𝑡
 𝛥𝑡 +
𝑑2𝑥(𝑡)
𝑑𝑡2
 
𝛥𝑡2
2
+. . .                                     (17) 
Figure 15. MD calculations are iterative. Form initial positions and velocities future and 
past positions can be calculated. Taken from Wikimedia-Knordlun. 
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The position x(t), the velocity dx(t)/dt, and the acceleration d2x(t)/dt2 are sufficient for 
numerical solution to the equations of motion if some approximation to account for 
higher order terms in the Taylor series can be made. For this single dimension, Newton’s 
second law describes the acceleration, 
 
                                                  
𝑑2𝑥(𝑡)
𝑑𝑡2
=  
𝐹𝑥
𝑚
                                                         (18) 
 
where 𝐹𝑥 is the component of the net force acting on the atom parallel to the direction 
of x. Determination of future acceleration, velocity and positions are calculated by 
integration of the equations of motion using integration algorithms. The Verlet 
algorithm uses the atomic positions and accelerations at time t and the positions from the 
prior step,x(t − Δt), to determine the new positions at t + Δt. 
 
                      𝑥(𝑡 +  𝛥𝑡) = 2𝑥(𝑡) − 𝑥(𝑡 − 𝛥𝑡) +
𝑑2𝑥(𝑡)
𝑑𝑡2
 𝛥𝑡2                                    (19) 
 
A slight modification of this, known as the leapfrog algorithm, is popular. The 
leapfrogalgorithm uses the positions at time t and the velocities at time t − (Δt/2) for the 
update of both positions and velocities via the calculated forces, F(t), acting on the atoms 
at time t, 
                            𝑥(𝑡 + 𝛥) = 𝑥(𝑡) +  
𝑑𝑥(𝑡)
𝑑𝑡
 (𝑡 +
𝛥𝑡
2
)𝛥𝑡                                          (20) 
 
                             
𝑑𝑥(𝑡)
𝑑𝑡
(𝑡 +
𝛥𝑡
2
) =
𝑑𝑥(𝑡)
𝑑𝑡
(𝑡 −
𝛥𝑡
2
) +
𝑑2𝑥(𝑡)
𝑑𝑡2
𝛥𝑡                                      (21) 
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These iterative calculations are performed every one to two femto-seconds for a set 
period determined usually by computational time and expense. Other parameters are 
determining factors during MD simulations, including temperature control, constraints, 
periodic boundary conditions, using implicit or explicit solvent, and pressure control [8].  
            Trajectory Analysis. A basic MD simulation is a minimization and 
 equilibration run designed to collect data of a system in equilibrium. Information on 
 thermodynamic variables is provided by the NAMD log file including temperature, 
 bond energy, total energy, pressure, volume and kinetic energy. These variables give 
 insight into the thermodynamic state of the entire system, but we also want to know 
 if the system is conformationally stable. For this, we can calculate the RMSD of the 
 protein backbone as a measure of the stability of the protein. If the RMSD is still 
 increasing at the end of the run, the protein is still searching for a lower energy state, 
 and indicates the system is not equilibrated. The RMSD is a numerical difference  
 between two structures. It is defined as: 
 
                                                 𝑅𝑀𝑆𝐷(𝑡) =  √
∑ |𝑟𝑖(𝑡)−𝑟𝑖
−0|2𝑁𝑖=0
𝑁
                                        (22) 
 
 Where N is the set of atoms at time t, with respect to the reference conformation. 
  |𝑟𝑖(𝑡) − 𝑟𝑖
−0|2  is the displacement of the ith atom at time t from the reference 
  position 𝑟𝑖
0. After the run, the RMSD values are plotted over time and although the 
  protein and RMSD values will always fluctuate, we expect the data line to flatten 
  out before the end of the simulation [85][86]. 
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MDM2 CASE STUDY: COMPUTATIONAL PROTOCOL UTILIZING PROTEIN 
FLEXIBILITY IMPROVES LIGAND BINDING MODE PREDICTIONS 
 
    Introduction 
            P53 is a tumor suppressor protein found in the nucleus of cells, which functions to 
respond to cellular stress by mediating cell-cycle arrest, senescence, or apoptosis in 
response to DNA damage, oncogene activation, and hypoxia [48][87]. Inactivation of the 
P53 pathway is found in the majority of human cancers and is facilitated by mutation or 
deletion of the TP53 gene or damage to cellular regulatory mechanisms [88][89]. The 
primary regulator of P53 is MDM2, an E3 ubiquitan ligase protein, which binds to P53 
marking it for degradation. In damaged cells, over-expression of MDM2 results in 
reduced levels of P53, initiating the onset of oncogenesis [62][90]. Chemotherapies 
attempt to block this interaction and recover the tumor suppression activity of P53 by 
introducing small non-peptide molecules designed to target and bind to the P53 binding 
domain of MDM2 [59].  Several small molecule inhibitors have been designed from lead 
compounds discovered via the structure-based virtual screening of chemical libraries 
performed by docking programs and many have entered and completed Phase 1 cancer 
drug clinical trials [47][60].  HTS evaluate thousands of small molecules and are a cost 
effective approach designed to rely on fast, accurate predictions, intended to isolate a 
small number of molecules as possible cancer therapeutics [15].  
            Molecular docking programs represent a critical tool in the early stages of 
structure-based drug design while providing important insights into molecular binding 
processes [91]. The focus on MDM2 as a target for cancer therapeutics and subsequent 
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literature underscores the importance of docking programs such as AutoDock and the 
more efficient, reliable alternative, Vina, for the quick and accurate screening of cancer 
drug candidates [92]. Many scientific articles have cited these programs and the programs 
themselves have been the focus of validation studies highlighting efficiencies and certain 
limitations. AutoDock has been shown to be reliable within 2 angstroms of the 
experimentally known binding site for smaller ligands targeting DNA and proteins, but 
struggles with larger ligands having 10 or more rotatable bonds due to the increased 
conformational search space [69][16][93]. This restriction has led to the use of a rigid 
receptor/flexible ligand protocol as standard methodology due to the computational 
challenges posed by incorporating protein flexibility [81][80]. This methodology fails to 
account for side-chain residue movement at binding site interfaces, resulting in a less 
reliable prediction of the ligands’ docked binding mode [94][9]. Invoking AutoDock’s 
side-chain flexibility feature accounts for some protein movement, but this adds to the 
conformational search space associated with a flexible ligand, which can reduce accuracy 
and increase computational costs [95].  
            Many parameters can be adjusted by the user for any particular experiment using 
AutoDock. This analysis focuses on improving ligand binding mode predictions through 
selective flexibility of the ligand and receptor utilizing AutoDock’s feature of protein 
side-chain flexibility, while employing the speed and accuracy of Vina to reduce 
computational time. However, it’s important to realize, AutoDock and Vina are two very 
different programs as they use a different scoring function and search method [21]. The 
results must be compared separately and it is for the user to determine the program best 
suited for their needs. Using Vina will determine if accuracy of the results is shared by 
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both, therefore, the user can take advantage of Vina’s computational speed and accuracy 
or AutoDock’s flexibility and large data output if desired. 
            The protocol followed for this study transfers flexibility from the ligand to the 
protein binding site residues resulting in improved ligand binding mode predictions of 
small medicinal compounds to the P53 binding site of MDM2, based on RMSD from the 
experimentally determined binding site (figure 16). Lowest RMSD values coincide with a 
majority of the rotatable bond flexibility transferred to the protein. This determination 
resulted from data collected from 90 docking runs using AutoDock and Vina. Further, a 
MD simulation revealed the minimized and equilibrated MDM2 protein shows 
considerable movement of binding site residues made flexible during docking 
calculations. The docking and MD results from this study highlights the importance of 
modeling protein flexibility for the determination of accurate binding mode predictions of 
small molecules to MDM2 in contrast to traditionally rigid docking approaches. This 
protocol could be especially useful for HTS of potential cancer drugs and other 
therapeutics targeting proteins and DNA. 
            An additional brief docking study of a cancer drug target suggests this protocol 
may be applicable to other structures. The study evaluated a cancer drug complexed with 
a protein enzyme and DNA (figure 17). Camptothecin is a substance, poison to human 
cells, it is produced by a tree native to China as a natural defense mechanism. In humans, 
it binds to topoisomerase, a critical enzyme responsible for binding to DNA in order to 
relax the helical structure during replication [96]. Camptothecin binds to the covalent 
topoisomerase -DNA complex and stabilizes the helical structure leading to DNA strand 
breaks that lead to the apoptosis of drug-treated cells. This drug is used to treat colorectal 
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cancer, ovarian and small cell lung cancers. While effective for about 30% of patients, 
the effects are temporary, due to topoisomerase resistance mutations [97]. Research has 
Figure 16. Snapshot of PDB structure 4JRG. The small molecule inhibitor shown 
in yellow is bound to the P53 binding domain of MDM2. The mesh surrounding 
the molecule is the surface rendering designed to highlight the full extent of the 
interactions with the protein. The re-docking experiments performed during this 
study uses the known binding site pictured here against AutoDock and Vina’s best 
predictions.  
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focused on not only understanding the mutations, but modifying the chemical structure of 
camptothecin to improve efficacy [98]. CADD utilizing docking methods can aide this 
Figure 17. Ligand TTG (yellow) is shown intercalated between DNA base 
pairs (blue) while bound to the topoisomerase enzyme (ribbon). This forms a 
ternary complex designed to stabilize the DNA in cancerous cells and disrupt 
replication during cell division. Research is now focused on topoisomerase 
mutations undermining the drug effectiveness possibly due to over-
accumulation of the drug in tumor cells or adoptive responses to DNA 
disruption. 
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effort by modifying and testing possible changes to the drug in silico, saving time and 
money during development.  
 
Methods and Materials 
 
               Standard docking experiments employ a rigid receptor/flexible ligand protocol 
while exploring conformational space within a specified grid box designated by the user. 
Results are assessed according to the binding free energy, which represents a measure of 
how securely the small molecule is attached to the desired area of a target molecule. The 
binding mode is then analyzed to ensure the small molecule’s correct location and 
geometry accompanies the top ranked binding energy. A successful re-docking will be 
within 2 angstroms of the experimentally known binding site and correspond to one of 
the top ranked binding energies [99][100]. In short, the sum of the energy of ligand and 
receptor separately is greater than the total energy when bound together. The difference is 
the binding free energy. A higher negative energy indicates a deeper potential energy 
well, a more stable complex, and more likely binding mode [7]. For this study, only the 
top ranked binding energy and corresponding RMSD from the known binding site was 
considered as a data point. 
            Experimental details. A set of four structures, representing small molecule 
inhibitors in complex with MDM2 was retrieved from the PDB (table 1). PDB codes: 
4JRG, 3LBK, 4IPF and 4ZYI. For each complex, the implemented protocol 
systematically distributed a total of 12 rotatable bonds between the ligand and receptor 
until all combinations were tested beginning with 0 flexible bonds for the ligand and 12 
for the receptor, and then 1 flexible bond for the ligand and 11 for the receptor and so on, 
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Table 1. Ligand and receptor parameters of structures tested. 
 
  PDB                                    Ligand                                           Receptor 
 Structure    Ligand Identifier    # of Rotatable Bonds      Binding Site Residues 
 
  4JRG                  I09                               12                    ILE57   ILE95   TYR 
 
                                                                                                                        HIS69   PHE      LEU 
 
                                                                                                                        HIS92   MET     VAL 
 
                                                                                                        LYS 
 
 
  4IPF                   1F0                              10                    HIS69     HIS92    GLY 
 
                                                                                                                        LEU50   LEU53   MET 
 
                                                                                                                        VAL       ILE57    GLN 
 
 
 
 
  4ZYI                 4TH                              9                     PHE55    PHE86   LEU 
 
                                                                                        GLN24   GLN72   HIS 
 
                                                                                        TYR67   TYR100  MET 
 
 
 
 
  3LBK                K23                              5                     ILE61    LEU      PHE 
 
                                                                                        ILE99   GLY      HIS 
 
                                                                                        VAL     MET    TYR100 
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using the notation (0,12) and (1,11) respectively. When the maximum number of 
rotatable bonds was reached inherent in each ligand, the remainder was transferred to the 
protein. Docking parameters for all calculations using AutoDock version 4.2 were 
adjusted to 100 runs with 2 x 107 energy evaluations and a grid box size of 60 Ǻ 62 Ǻ 62 
Ǻ centered on the ligand with .375 Å grid spacing (figure 18). The grid box for Vina 
version 1.1.2 was set to 27 Ǻ 27 Ǻ 27 Ǻ centered on the ligand with a 1 Å grid spacing 
and the exhaustiveness was set to 12. The grid box created for AutoDock and Vina runs 
are the same size, but the spacing is different. This accounts for the apparent smaller grid 
box of Vina whose spacing is 1 Å.  The LGA was designated as the AutoDock search 
method, while all other settings for both programs were kept at default parameters. 
            The structure representing camptothecin in complex with topoisomerase and 
DNA was retrieved from the PDB, (PDB code: 1RRJ). The ligand (camptothecin) 
identifier used for this study is TTG, which is the hydrolyzed version (1 extra Oxygen 
and 2 extra Hydrogen) of another form of the drug TTC. The ligand has 9 inherent 
rotatable bonds instead of the 5 found with TTC. All settings were kept consistent with 
those used for MDM2 docking runs apart from the search grid box. The grid box used for 
this docking was 60 Ǻ 72 Ǻ 60 Ǻ (figure 19). The 72 Ǻ reflects the unique geometry 
associated with a protein bound to DNA. This translates to a Vina grid box of 22.5 Å 27 
Å 22.5 Å. Instead of a systematic evaluation of each configuration of ligand and protein 
flexibility, the docking study for 1RRJ only contained two configurations. One, using the 
standard protocol of a flexible ligand and rigid protein, and the second, using the rigid 
ligand protocol transferring 12 rotatable bonds to the binding site residues of the protein. 
The notation is (9,0) and (0,12) respectively. This is sufficient to evaluate the merits of a 
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rigid ligand protocol in contrast to the rigid protein protocol currently employed by HTS 
without exploring all combinations of flexibility because it explores the only other 
pragmatic option for large virtual screenings. When evaluating thousands of small 
molecules, it becomes impractical to select the optimal number of rotatable bonds for 
each ligand. Alternatively, a target protein could be prepared with selected flexible  
 
 
 
Figure 18. Conformational search grid box for all MDM2 docking runs as rendered 
by AutoDock tools. The protein residues are labeled by color. 
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binding site residues, while keeping all ligands rigid without disruption of the screening. 
This would allow for the modeling, at least to a small extent, of binding site flexibility. 
The residues and number of rotatable bonds for the (0,12) configuration of 1RRJ include: 
Arg364 (4), Asp533 (2), Lys532 (5) and Glu356 (1). 
Figure 19. Grid box for two docking runs of structure 1RRJ. The box must be large 
enough to encompass the binding site flexible residues of the protein and the 
experimentally known ligand binding site. Failure to make the box large enough will 
result in positive binding energy.  
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            Ligand/Protein Preparation. All structures were retrieved from the PDB and 
initially prepared for docking using Chimera software [101] . The ligand was separated 
from the protein and a short energy minimization was applied to each structure for a 
duration of 10 steps. Hydrogen atoms were added, water molecules removed, and 
Gasteiger charges were automatically added to the ligand and protein. The necessary files 
for docking were prepared in AutoDock tools (ADT). When files are imported into ADT, 
they are checked for polar hydrogens, water molecules and proper charges. The rotatable 
bonds of the ligand were altered using the ‘choose torsions’ option. Here, the initially 
flexible bonds of the ligand can be adjusted for docking and saved. A flexible residue file 
was created for the rotatable bonds of the selected protein binding site residues in 
addition to a separate rigid protein file. The identical grid box was created for all 
structures tested using AutoDock. The grid box values for Vina dockings are placed 
directly into the Vina configuration file (See appendix A for example input files).  
            AutoDock/Vina Docking Output.  AutoDock results are ranked according to the 
highest negative binding free energies and corresponding RMSD values from the 
experimentally determined binding site. Each of the configurations tested produced 100 
predicted binding sites that were clustered and ranked. A cluster refers to dockings within 
2 Ǻ of each other and they are also ranked according to the binding free energy. The 
number of runs parameter set by AutoDock users instructs the program to conduct, in this 
case 100 separate searches beginning from a random location inside the designated grid 
box. Each run ends when the set number of energy evaluations have been reached in an 
attempt to find the global minimum energy. Vina’s results also rank dockings according 
to the binding free energy. However, Vina’s top ranked binding energy always 
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corresponds to a 0 RMSD regardless if the predicted binding mode matches the 
experimental structure. The subsequent RMSD values are in relation to this top ranked 
pose. Determining if Vina and AutoDock can converge on a similar binding mode can be 
accomplished utilizing visualization software, which can directly compare the 
experimentally known structure to both programs best prediction. AutoDock and Vina 
share functional commonalities including the global optimization of the scoring function, 
pre-calculation of grid maps, and the pre-calculation of distant dependent pair-wise 
energetics between each atom type. However, they employ a different scoring function 
and algorithms to obtain binding free energies. Conveniently, both programs utilize the 
same ligand, receptor, and flexible residue files. This allows for a seamless transition 
between the two programs when the input files are prepared.  
 
 
Results and Discussion 
 
            The MDM2 oncoprotein is a current target for cancer drug development in the 
form of small molecule inhibitors designed to firmly attach to its P53 binding domain, 
thus blocking P53/MDM2 interaction. The physical and chemical structure of MDM2 has 
been widely studied and a variety of crystallized structures have been developed. Many 
small molecule inhibitors have been crystallized complexed with the protein including 
many cancer drugs. This has enabled a thorough understanding of the binding site domain 
of MDM2 inhibitors. This domain contains 9 or 10 binding site residues depending on the 
crystal structure, each with between 1 and 4 rotatable bonds. This research sought to 
improve binding mode predictions using the popular docking programs AutoDock and 
Vina through the selective flexibility of both ligand and binding site residues using four 
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crystallized structures obtained from the PDB.   
            The docking results indicate best binding mode predictions correspond to ligand 
rigidity and protein flexibility for all structures tested using either program (table 2). 
Further, configurations of complete ligand rigidity (0,12), produced smaller RMSD 
values compared to the standard protocol for all structures. Surprisingly, supplying 
additional rotatable bonds well past AutoDock’s usual accuracy threshold improves 
binding site predictions when this additional flexibility is transferred to the protein. This 
was not expected, since AutoDock usually experiences reduced accuracy as the number 
of rotatable bonds approach and exceed 10. The PDB structure 3LBK represents a small 
molecule in complex with MDM2 containing only 5 inherent rotatable bonds, but 
AutoDock’s most likely docked pose has it 2.20 Ǻ from the experimentally known site 
using the standard protocol. This improves to .51 Ǻ when 12 rotatable bonds are supplied 
to selected binding site residues (figure 20). A snapshot of each of these two binding 
modes highlights the contrast between AutoDock’s best prediction and the 
experimentally known binding geometry. From figures 21 and 22, we can see the 
juxtaposition of predicted and experimental geometries of configuration (5,0) 
representing the standard protocol and (0,12), the rigid ligand docking. The geometry and 
proximity of the standard protocol docking is not nearly as precise as (0,12), shown by 
the 2.20 Å RMSD as compared to .51 Å. from the experimentally known site using the 
standard protocol. This improves to .51 Ǻ when 12 rotatable bonds are supplied to 
selected binding site residues (figure 20). A snapshot of each of these two binding modes 
highlights the contrast between AutoDock’s best prediction and the experimentally 
known binding geometry. From figures 21 and 22, we can see the juxtaposition of 
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Table 2. AutoDock results from rigid ligand-flexible residue configuration (green)  
contrasted with the standard protocol methodology (red). 
   PDB                                            Binding                       Binding Site Flexible Residues 
Structure     RMSD(Ǻ)       Free Energies (Kcal/mol)            (# of rotatable bonds) 
 
 
4JRG         .66        3.84          -10.25      -9.63              LEU(2)     ILE57(2)  HIS(2) 
  
                                                                                       VAL(1)    ILE95(2)  LYS(3) 
 
 
 
 
 
4IPF          .64        1.68         -14.28     -12.29            LEU50(1)   LEU53(2)  ILE(2) 
                           
                                                                                     HIS69(2)    HIS92(2)  VAL(1) 
                                                                                                               
                                                                                      TYR(2) 
 
 
 
 
 
4ZYI         .44          .77          -20.58     -12.63           GLN24(1)    GLN72(2)  LEU(2) 
 
                                                                                     TYR67(2)    TYR100(2)  PHE(1) 
 
                                                                                      HIS(2) 
 
 
 
 
 
3LBK       1.02       3.52          -11.14     -10.32           LEU(2)     MET(3)     VAL(1) 
 
                                                                                     HIS(2)      ILE(2)       TYR(2) 
 62 
 
predicted and experimental geometries of configuration (5,0) representing the standard 
protocol and (0,12), the rigid ligand docking. The geometry and proximity of the standard 
protocol docking is not nearly as precise as (0,12), shown by the 2.20 Å RMSD as 
compared to .51 Å.     
            The ligand bound to MDM2 in structure 4JRG contains 12 rotatable bonds, which 
is well above AutoDock’s validated limit for a successful docking. Using the standard 
protocol (12,0), AutoDock’s best prediction is 2.83 Å from the experimentally 
determined binding mode, while a rigid ligand protocol (0,12), yields a prediction within 
.58 Ǻ (figure 23). The trendline shown is indicative of all MDM2 structures tested. As 
The ligand takes on more flexibility, the RMSD values rise until, most notably in this 
example, spikes at 2.83Å with a rigid protein. The RMSD values of configurations 
between the two extremes fluctuate, but it is difficult to infer from these results the reason 
for the anamolies of certain configurations showing smaller RMSD values as with (7,5), 
next to an almost doubling of RMSD (6,6). Due to the randomness componet of the 
search method, we do expect slight differences in results to accompany identical docking 
trials. The same input files run on the same system using the same version of the program 
is not likely to produce identical results. This does not account for the consistent patern of 
increased RMSD values found in these docking calculations. The pattern we see of 
increased fluctuation, especially of those configurations with almost equal number of 
rotatable bonds attributed to the ligand and protein, is probably due to the selection of 
rotatable      bonds (figure 24). When a ligand with 12 inherent rotatable bonds has 6 held 
rigid as with (6,6), and is docked to a protein with 6 rotatable bonds within the binding 
site residues, we can anticipate how the result may change when we simply reverse the 
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rigid and flexible bonds of the ligand. Due to the randomness of the search and the 
enourmous amount of possible combinations, we can only infer from the pattern we see 
here a likely strategy for success. In the case of MDM2 at least, the diversity associtated  
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Figure 20.  RMSD values corresponding to the top ranked binding energies for all 
configurations indicate a total rigid ligand (0,12) has the lowest RMSD value of .51 
Ǻ. As the number of rotatable bonds become more evenly distributed, binding 
mode accuracy declines.  
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Figure 21. The standard protocol docking pose for 3LBK (5,0) using AutoDock 
with an RMSD of 2.20 Ǻ (green). In contrast with the experimentally determined 
structure (yellow). 
 
Figure 22. 3LBK rigid ligand configuration (0,12) using AutoDock with RMSD 
of .51 Ǻ (green). In contrast to the experimentally known structure (yellow). 
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with equal flexibility of ligand and protein reduces accuracy. We would expect (6,6) to 
have the lowest RMSD values if just modeling flexibilty was essential for improved 
binding mode predictions. 
            Another notable result from this study is the large RMSD values for those 
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Figure 23. The standard protocol (12,0) configuration shows an RMSD of 2.83 Ǻ with the 
ligand having 12 rotatable bonds in contrast to a rigid ligand and all 12 rotatable bonds 
transferred to the MDM2 protein represented by configuration (0,12) with an RMSD of 
.58 Ǻ. 
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configurations representing a completely flexible ligand with limited protein binding site 
flexibility. For 3LBK, this is docking run (5,7). Although this would seem the ideal 
distribution of flexibility as it incorporates the inherent flexibility of the ligand and 
binding protein residues, the RMSD value is 3.81 Ǻ, far above the rigid ligand docking of 
.51 Ǻ. The same is true of 4JRG, with the (10,2) configuration showing an RMSD of 1.46 
Figure 24. Snapshot of prepared ligand for structure 4JRG, configuration (2,10). The 
red lines indicate the fixed portions of the small molecule. The magenta lines indicate 
bonds that could be selected as rotatable, while the green lines are selected rotatable 
bonds. The selection of rotatable bonds for all ligands was based on allowing the 
outer-most bonds to become flexible first and then move inward as flexibility 
increased. If two entirely different bonds were chosen, we can see how the docking 
calculation may have changed. This is also true for protein flexibility where the same 
general approach was used to select flexibility. 
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Å compared to .58 Å.  This is important because the (5,7) and (10,2) configuration of 
3LBK and 4JRG respectively would be applicable to HTS as it does not require ligand 
modification or a change in protein flexibility once the screening starts, and would 
simulate in part, both protein and ligand binding dynamics more accurately than the 
standard protocol. This study finds a fully flexible ligand in combination with selective 
protein binding site flexibility fails to optimize the binding mode predictions. Docking 
results for structures 4IPF and 4ZYI, also show higher RMSD values for this distribution, 
with values of 1.64 Ǻ and 3.75 Ǻ respectively (figure 25 and 26). An explanation for the 
poor docking results could be the consequence of re-docking a rigid ligand, and the built-
in bias of the small molecule to assume the same binding mode associated with the 
experimentally known structure. However, the same bias is present using a rigid protein 
protocol, as the protein’s binding site residues are essentially frozen in the optimal 
binding mode as is the rigid ligand. When the ligand and protein both have flexibility, 
this bias is partially removed and predicting binding modes close to the experimental 
structure becomes more difficult. In fact, all structures excluding 4JRG, produced higher 
RMSD values compared to both the standard and rigid ligand protocols when a fully 
flexible ligand was in combination with selected binding site flexibility. 
            A more exhaustive examination of possible combinations of ligand and protein 
flexibility may, for any particular complex, improve the ligand binding mode prediction 
and improve RMSD values. The results from this study only indicates applying a rigid 
ligand protocol will produce lower RMSD values compared to the standard protocol for 
MDM2. This is of some importance considering the focus of medicinal interest on 
MDM2 and considering the amount of MDM2 targeted inhibitors developed as cancer 
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therapeutics. For HTS, an exhaustive examination of all possible flexibility is not a 
practical strategy as thousands of drug candidates are screened and evaluated. A large 
assortment of small molecules is evaluated with varying chemical and physical 
properties, including flexibility. There is little doubt more robust scoring functions  
0.49
1.37
0.69
3.55
0.61
0.72
1.37
2.66
2.81
1.39
1.64
1.52
0
1
2
3
4
    (0,12)    (1,11)    (2,10)   (3,9)   (4,8)   (5,7)   (6,6)   (7,5)    (8,4)    (9,3)    (10,2)     (10,0)
R
M
SD
 (
Å
) 
 
Number of Rotatable Bonds
(ligand,receptor)
AutoDock: 4IPF
Figure 25. A fully flexible ligand with 2 flexible binding site rotatable bonds 
(10,2) yields a larger RMSD value of 1.64Å compared to both the standard (10,0) 
and rigid ligand protocol (0,12). 
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and search methods, along with increased computational speed from advancing computer 
architecture, will improve docking results.  
            The new scoring function and search method employed by Vina has improved 
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Figure 26. The flexible ligand configuration (9,3) produces an RMSD value much larger 
than all other combinations. This docking result is the exception as the rigid ligand (0,12) 
does not produce the lowest RMSD value, but is still well within the successful docking 
range of 2Å. 
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speed and binding mode predictions and is probably more suited for HTS then AutoDock. 
However, AutoDock does hold some advantages over Vina in terms of changing docking 
parameters and output. Vina’s docking results are not nearly as extensive as AutoDock. 
Vina supplies the top ten binding energies but does not associate a RMSD value to the 
top ranked binding free energy (figure 27). Consequently, Vina results are not charted for 
this study in terms of RMSD as with AutoDock. Confirmation of a successful docking 
and comparison to AutoDock must be accomplished using renderings of the binding 
mode in direct contrast to the experimentally determined structure. Comparing binding 
free energies is not applicable for two reasons. As discussed previously, AutoDock and 
Vina use different methods to determine binding free energy with both using many 
assumptions and estimates. This becomes especially problematic when adding flexibility 
as the loss of entropy is merely a weighted constant and not calculated. If this constant is 
in error by just .20 kcal/mol for structure 3LBK, a configuration such as (0,12) will have 
a widely different free energy than configuration (5,0). It would not be valid to compare 
the two binding energies or to compare the binding energies between the two programs. 
The ranking of the free energy is only truly reliable within the same docking run. 
Secondly, the AutoDock lowest binding energy does not always correspond to the 
binding mode most closely associated with the experimental structure. A higher binding 
energy may correspond to a slightly better RMSD value close to the top ranked energy 
possessing a higher RMSD, but with an almost equally accurate prediction.   
            An important advantage of using Vina along with a rigid ligand protocol for 
MDM2 is that it mitigates concerns of additional computational time and costs while 
allowing for a flexible protein and more accurate binding prediction. Vina’s 
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multithreaded configuration can drastically reduce computational time while providing 
accurate results when docking ligands, as in this study, with 12 rotatable bonds. Vina’s 
binding prediction for structure 4JRG mirrors AutoDock’s best result of .58 Å as shown 
in figures 28 and 29. However, Vina’s calculation took less than 2 minutes, while the 
AutoDock calculation lasted 15 hours. The increased speed is not surprising, as this has 
been shown previously, but while transferring all flexibility to the protein, Vina also 
produced a noticeable improvement of binding mode predictions as compared to the 
standard protocol with no increase in computational time [102]. Applying a rigid ligand 
protocol when using Vina for HTS concerning MDM2 affords the consideration of larger 
ligands without reduced accuracy or increased computational costs. 
            The improved determination of binding geometries using a rigid ligand protocol is 
probably best explained by the physical structure of the P53 binding domain of MDM2. 
The binding domain as seen clearly in figure 16 sits inside a pocket flanked by residues 
not embedded within the protein. These residues can fluctuate during the binding process, 
allowing a rigid ligand to enter while the protein conforms to the small molecule 
according to the energy landscape determined by its chemical structure as evidenced by 
the before and after snapshots of figure 32. The modeling of movement of critical 
residues in the same way a flexible ligand would be modeled may explain how the rigid 
ligand can enter the binding site and settle in the preferred binding mode. It is important 
to remember the program moves both the ligand’s and protein’s bonds randomly, while 
searching for the local energy minima. Modeling the protein movement may be more 
essential in finding the global minimum and facilitating changes to ligand geometry to 
more accurately match the true binding orientation. 
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            Molecular Dynamics Analysis. A time dependent evaluation of binding site 
residue movement can be conducted with a classical MD simulation of the MDM2 
protein. Using the crystallized protein structure of the 4IPF complex, a simulation 
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Figure 27. Binding free energy results from 4IPF using Vina shows a similar pattern 
to AutoDock. The rigid ligand docking has a much higher negative free energy 
compared to the standard protocol indicating a more likely binding mode. Also, the 
combinations with a more equal distribution of rotatable bonds show a higher 
fluctuation in binding energies. This is important because both programs reach this 
result using different scoring and search methods.  
 73 
 
                   
   
 
 
 
 
                
 
 
Figure 29. AutoDock’s prediction of rigid ligand docking of 4JRG (0,12) shown 
in green. This docked pose is .58 Å from the experimentally known docked 
ligand (yellow). 
 
 
Figure 28. Vina’s prediction of rigid ligand docking of 4JRG (0,12). This binding 
mode prediction (green) is slightly closer to the experimentally known pose 
found by AutoDock in figure 29. 
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was performed using NAMD. The protein is prepared and necessary files created using 
VMD (visual molecular dynamics), the graphical user interface (GUI) designed to work 
with NAMD for the preparation, evaluation and visualization of MD simulations 
(appendix B). A minimization and equilibration simulation allows for the determination 
of residue mobility before interaction with the ligand from average RMSD values 
calculated during equilibration. The data provides valuble insights toward understanding 
the protein residue dynamics the ligand encounters as it enters the MDM2 binding site 
and searches for the preferred binding mode. The  simulation lasted .5 ns with a 1 fs time 
step at a constant temperature of 310K in an explicit solvent (figure 30). The long run 
time ensures the protein will be able to reach equilibrium providing reliable data for the 
residue RMSD calculation. The use of an explicit solvent accounts for the aqueous 
enviroment and the desolvation energy associated with removing water molecules from 
binding site interfaces. Results  show the residues made flexible for docking run (0,12) 
fluctuate between 1.4 and 3.2 Å, with binding site residues HIS 69, HIS 92 and TYR 96 
all moving an average of 3 Å (figure 31). The RMSD values serve to quantify movement 
of the protein in equilibrium while affirming the importance of modeling residue 
flexibility during docking calculations (figure 31). Although flexibility modeled by 
docking is just the limited rotation of bonds, with bond lengths and angles kept constant, 
the change observed from the binding site residues can be pronounced. The before and 
after snapshot of binding site residues from figure 32 highlights the change in orientation 
necessary to accommodate a successful docking within .49 Å of the known structures 
ligand binding mode. This suggests ligand flexibility may not be as essential as modeling 
protein conformation changes that accommodate a small molecule during the binding 
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process. Analysis using Ramachandran plots confirm the protein residues settle 
 
in allowed regions according to possible φ and ψ dihedral angles. A selection of these 
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Figure 30. The MDM2 protein as represented by crystal structure 4IPF was used to 
evaluate fluctuation of specific binding site residues. The equilibration simulation 
should run long enough as to let the system stabilize according to RMSD 
fluctuation. Any data collected before that will be artificially altered by the heat 
energy placed into the system. The graph above shows flattening out, indicating the 
system is in equilibrium. This allows data to be collected for individual residues in 
terms of RMSD from their equilibrium position providing a better understanding of 
the binding site dynamics. 
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plots can be found in appendices C through E. The Ramachandran plots ensure the 
conformation changes predicted by the programs are theorhetically possible and therefore 
a valid representation of the biological system.  
            Data Mining Analysis. Given the large number of potential rotatable bond 
combinations between the ligand and protein, a ‘a priori’ knowledge of the optimal 
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Figure 31. A Molecular dynamics simulation was performed using NAMD to 
establish residue fluctuation at equilibrium. The red markers indicate binding site 
residues made flexible for the 4IPF (0,12) docking run. The missing data results 
from the loss of the first and last twenty residues while crystallizing MDM2, which 
is typical for this structure. 
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distribution of ligand/protein flexibility would be ideal considering testing all possible 
considerations would be impractical. For example, 3lbk configuration (5,7) contains 792 
possible combinations. As a guide, we can employ a data mining approach where each of 
the potential bonds is assigned as one of the parameters to be turned off or turned on (0 or 
1). We can then seek the weight factor of each of these parameters by supposing the total  
 
 
Figure 32. Final positions of flexible binding site residues (green) for 4IPF (0,12) 
indicates residues LEU, TYR, VAL and HIS have shifted considerable from the 
experimentally determined geometry (yellow). Due to the time independent nature of 
docking, we can only capture before and after states of the complex. The protein and 
ligand have been removed for clarity. 
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cohesive energy as well as RMSD can be quantitatively  linked to a linear regression as a 
superposition of all the parameters: 
 
                                  𝐸 =  ∑ 𝑊𝐿𝑖𝐿𝑖
𝑁
𝑖=1 + ∑ 𝑊𝑝𝑖𝑃𝑖
𝑀
𝑖=1                                                      (23) 
 
                                RMSD = ∑ 𝑊𝑠𝑖𝑆𝑖 
𝑁
𝑖=1 +  ∑ 𝑊𝑇𝑖𝑇𝑖
𝑀
𝑖=1                                                  (24) 
Where: 
Li = 0 or 1 (a binary for each rotatable bond in the ligand) for energy 
WLi = weight factors of each Li for energy 
 Pi = 0 or 1 (a binary for each rotatable bond in the residues) for energy 
WPi = weight factors of each Pi for energy 
                Si = 0 or 1 (a binary for each rotatable bond in the ligand) for RMSD 
WSi = weight factors of each Li for RMSD 
Ti = 0 or 1 (a binary for each rotatable bond in the residues) for RMSD 
WTi = weight factors of each Ti  for RMSD 
  
The number of parameters will depend on the total number of rotatable bonds between 
the ligand and protein. Each parameter can be toggled on or off corresponding to a 
flexible or rigid bond. Data mining calculations using the energy, RMSD and distribution 
of flexibility data as shown in table 3 yielded promising results as particular ligand and 
protein rotatable bonds showed strong weighted constants which match closely with low 
RMSD values and high negative binding energies. This simplified method certainly may 
not generate fully recoverable linear superposition for a complex docking process, but at 
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least it does provide a guidance, based on a given number of allotted rotatable bonds, as 
to which rotatable bonds that are preferred to be “activated”. The weight functions may 
also indicate the relative level of importance quantitatively on activating a specific set of 
rotatable bonds. Further, we can probably identify if there is a potential negative effect in 
 
Table 3. Structure 3lbk bond toggle displays the activation status of each bond for each 
configuration in addition to the correspond energy and RMSD values. 
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activating certain rotatable bonds toward the total energy and/or RMSD through the 
formation of negative weight factors. Using this technique, we can locate particular bonds 
within binding site residues to activate that will most likely lead to a successful docking. 
The linear regression analysis of structure 3lbk indicated activation of bonds P4 and P9 
play a significant role in energy optimization while P8 improves RMSD values. Bonds 
L4 and L8 play a significant role, both negative and positive, for RMSD. Figure 33 shows 
a small nutlin derivative and MDM2 with each ligand and protein labeled for a clear 
representation of the 3D structure. 
 
 
 
             Analysis of Cancer Drug Camptothecin. A brief study of a rigid ligand 
protocol in contrast to the standard protocol was conducted testing AutoDock  and Vina’s 
Figure 33. Structure 3lbk with protein and ligand labels together with data mining 
analysis allows for a clear 3D assessment of the residues and rotatable bonds most critical 
for a successful docking.  
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binding mode predictions of a small molecule complexed with DNA and a protein 
enzyme. This forms a ternary binding since the ligand is bound to the protein while the   
protein is bound to DNA. This complex is distinct from MDM2 and provides a suitable 
test case in order to evaluate if the successful rigid ligand docking regarding MDM2 was 
a special case or could be applicable to other systems. The standard protocol was applied 
using both programs for the initial docking allowing all 9 of the ligands’ rotatable bonds 
to be flexible (9,0), followed by a rigid ligand docking, with 12 rotatable bonds being 
assigned to selected protein residues.  
            The top ranked binding mode for (9,0) using AutoDock was 1.14 Å from the 
experimentally determined binding site, while the rigid ligand docking was within .74 Å. 
In this case, both re-docking calculations would be considered successful as they are both 
within 2 Å of the known binding area, but as with MDM2, the rigid ligand docking 
produces a noticeable improvement (figures 33 and 34). Vina results also show a more 
precise orientation utilizing protein flexibility evident from the comparison of figures 35 
and 36. The noticeable exception of this study is the fact AutoDock’s best binding mode 
prediction is actually closer in orientation to the known structure as compared to Vina in 
contrast to all MDM2 calculations. This is surprising because Vina, as mentioned 
previously, out performs AutoDock in both speed and accuracy. As the parameters for 
both programs were not changed, the difference in scoring and search method  in addition 
to the chemical and physical structure of the complex  may explain AutoDock’s superior 
prediction. Given this result, along with the more comprehensive findings from this 
research, it further serves to illustrate the importance of testing and validating these 
programs for optimum performance and results.               
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Figure 34. AutoDock standard protocol using a flexible ligand shows the contrast between 
the experimental orientation (yellow) and predicted binding mode (green).  
Figure 35. AutoDock utilizing protein flexibility improves binding mode accuracy. 
Protein flexible residues are shown in green. 
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Figure 36. Vina’s top ranked pose for (9,0) appears to be well within 2 Å of known 
structure, but struggles to match orientation at the far left end. 
Figure 37. Vina utilizing protein flexibility improves orientation of ligand due to 
ligand rigidity within the binding domain. 
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CONCLUSION 
 
 
 
            Recovery of the P53 tumor suppressor pathway via small molecule inhibitors of 
onco-protein MDM2 highlights the critical role of computational methodologies in 
targeted cancer therapies. Improved binding mode predictions of small molecule 
inhibitors targeting the MDM2 protein was achieved with AutoDock and Vina using a 
systematic distribution of 12 rotatable bonds between the ligand and protein. This study 
found a rigid ligand in combination with flexible binding site residues produced lower 
RMSD values from the known binding site when compared to standard rigid receptor 
docking. Further analysis of the flexible binding site residues found considerable 
movement illustrated by a MD simulation and examination of the predicted final 
positions and experimentally determined positions of the selected residues. An additional 
evaluation of a DNA targeted cancer drug also produced improved ligand binding mode 
results incorporating the rigid ligand protocol. The modeling of residues located within 
the binding site were found to be more determinate than modeling ligand flexibility. 
Docking runs simulating a fully flexible ligand, in addition to 7,3 and 2 rotatable bonds 
transferred to MDM2, failed to come as close as a rigid ligand to the experimentally 
known structure. Adopting a rigid ligand-flexible protein docking protocol for future 
medicinal studies of MDM2 using Vina in particular, will enable accurate, fast 
predictions of MDM2 binding modes of small molecules with 12 and possibly more 
rotatable bonds.  
            Future studies will determine if this protocol may be applied to other proteins or 
DNA targets of medicinal interest. The emergence of molecular docking as an essential 
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tool for SBDD has fostered many clinical studies as well as exhaustive validation studies. 
The continued evaluation and optimization of these programs complimented by advanced 
computer architecture will aide in reducing the cost of cancer drug development, as well 
as foster new insights into bio-molecular binding processes. 
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APPENDICES 
 
Appendix A 
            Sample of Input Files For Docking Experiments  
Ligand File 
REMARK  0 active torsions: 
REMARK  status: ('A' for Active; 'I' for Inactive) 
REMARK       I    between atoms: N1_1  and  C10_23  
REMARK       I    between atoms: C5_2  and  C51_4  
REMARK       I    between atoms: C4_5  and  C41_7  
REMARK       I    between atoms: C2_9  and  C21_10  
REMARK       I    between atoms: C10_23  and  N10_25  
REMARK       I    between atoms: N12_28  and  C15_49  
REMARK       I    between atoms: C24_33  and  C30_34  
REMARK       I    between atoms: C26_38  and  O27_39  
REMARK       I    between atoms: O27_39  and  C28_40  
REMARK       I    between atoms: C16_43  and  C17_44  
REMARK       I    between atoms: C16_43  and  C15_49  
REMARK       I    between atoms: C17_44  and  S17_45  
ROOT 
ATOM      1  N1  1F0 A          12.567   8.335  35.668  0.00  
0.00    -0.226 N  
ATOM      2  C5  1F0 A          11.695   9.079  34.712  0.00  
0.00     0.096 C  
ATOM      3  C57 1F0 A          10.610   8.150  34.083  0.00  
0.00     0.041 C  
ATOM      4  C51 1F0 A          12.522   9.750  33.579  0.00  
0.00    -0.021 A  
ATOM      5  C4  1F0 A          11.040  10.172  35.653  0.00  
0.00     0.111 C  
ATOM      6  C47 1F0 A           9.767   9.671  36.400  0.00  
0.00     0.045 C  
ATOM      7  C41 1F0 A          10.778  11.519  34.951  0.00  
0.00    -0.018 A  
ATOM      8  N3  1F0 A          12.042  10.275  36.747  0.00  
0.00    -0.255 NA 
ATOM      9  C2  1F0 A          12.808   9.256  36.742  0.00  
0.00     0.134 C  
ATOM     10  C21 1F0 A          13.874   9.070  37.782  0.00  
0.00     0.045 A  
ATOM     11  C56 1F0 A          13.883  10.041  33.743  0.00  
0.00     0.007 A  
ATOM     12  C55 1F0 A          14.610  10.691  32.750  0.00  
0.00     0.021 A  
ATOM     13  C54 1F0 A          13.989  11.076  31.567  0.00  
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0.00     0.041 A  
ATOM     14 CL5  1F0 A          14.895  11.887  30.337  0.00  
0.00    -0.084 Cl 
ATOM     15  C53 1F0 A          12.635  10.815  31.385  0.00  
0.00     0.021 A  
ATOM     16  C52 1F0 A          11.910  10.159  32.380  0.00  
0.00     0.007 A  
ATOM     17  C42 1F0 A           9.556  11.785  34.315  0.00  
0.00     0.008 A  
ATOM     18  C43 1F0 A           9.354  12.981  33.629  0.00  
0.00     0.021 A  
ATOM     19  C44 1F0 A          10.379  13.922  33.552  0.00  
0.00     0.041 A  
ATOM     20 CL4  1F0 A          10.137  15.393  32.673  0.00  
0.00    -0.084 Cl 
ATOM     21  C45 1F0 A          11.600  13.672  34.172  0.00  
0.00     0.021 A  
ATOM     22  C46 1F0 A          11.794  12.482  34.871  0.00  
0.00     0.008 A  
ATOM     23  C10 1F0 A          12.978   7.059  35.425  0.00  
0.00     0.310 C  
ATOM     24  O10 1F0 A          13.183   6.667  34.294  0.00  
0.00    -0.253 OA 
ATOM     25  N10 1F0 A          13.169   6.220  36.487  0.00  
0.00    -0.275 N  
ATOM     26  C14 1F0 A          13.880   4.941  36.289  0.00  
0.00     0.160 C  
ATOM     27  C13 1F0 A          14.711   4.566  37.526  0.00  
0.00     0.148 C  
ATOM     28  N12 1F0 A          13.928   4.572  38.814  0.00  
0.00     0.249 N  
ATOM     29  C12 1F0 A          13.249   5.917  38.965  0.00  
0.00     0.148 C  
ATOM     30  C11 1F0 A          12.377   6.267  37.741  0.00  
0.00     0.160 C  
ATOM     31  C22 1F0 A          13.559   9.415  39.098  0.00  
0.00     0.015 A  
ATOM     32  C23 1F0 A          14.477   9.252  40.134  0.00  
0.00     0.005 A  
ATOM     33  C24 1F0 A          15.758   8.750  39.887  0.00  
0.00    -0.040 A  
ATOM     34  C30 1F0 A          16.797   8.569  41.017  0.00  
0.00    -0.013 C  
ATOM     35  C33 1F0 A          17.792   9.754  40.991  0.00  
0.00     0.016 C  
ATOM     36  C31 1F0 A          17.589   7.246  40.846  0.00  
0.00     0.016 C  
ATOM     37  C25 1F0 A          16.098   8.462  38.559  0.00  
0.00     0.038 A  
ATOM     38  C26 1F0 A          15.172   8.596  37.515  0.00  
0.00     0.086 A  
ATOM     39  O27 1F0 A          15.527   8.251  36.223  0.00  
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0.00    -0.346 OA 
ATOM     40  C28 1F0 A          16.855   7.848  35.817  0.00  
0.00     0.164 C  
ATOM     41  C29 1F0 A          16.837   7.543  34.313  0.00  
0.00     0.035 C  
ATOM     42  C32 1F0 A          16.163   8.516  42.435  0.00  
0.00     0.016 C  
ATOM     43  C16 1F0 A          14.280   4.213  41.357  0.00  
0.00     0.176 C  
ATOM     44  C17 1F0 A          15.260   3.679  42.435  0.00  
0.00     0.530 C  
ATOM     45  S17 1F0 A          14.568   4.133  43.989  0.00  
0.00    -0.280 S  
ATOM     46  C19 1F0 A          15.491   3.473  45.350  0.00  
0.00     0.666 C  
ATOM     47  O17 1F0 A          13.278   3.527  44.023  0.00  
0.00    -0.525 OA 
ATOM     48  O18 1F0 A          14.693   5.552  44.050  0.00  
0.00    -0.525 OA 
ATOM     49  C15 1F0 A          14.886   4.237  39.941  0.00  
0.00     0.141 C  
ATOM     50 2HN1 1F0 A          13.190   3.846  38.764  0.00  
0.00     0.200 HD 
ENDROOT 
TORSDOF 10 
 
Flexible Residue File 
 
BEGIN_RES LEU A  50 
REMARK  2 active torsions: 
REMARK  status: ('A' for Active; 'I' for Inactive) 
REMARK    1  A    between atoms: CA   and  CB   
REMARK    2  A    between atoms: CB   and  CG   
ROOT 
ATOM      1  CA  LEU A  50       9.533   9.929  29.079  1.00 
10.27     0.177 C  
ENDROOT 
BRANCH   1   2 
ATOM      2  CB  LEU A  50       8.870  10.875  30.081  1.00 
10.02     0.038 C  
BRANCH   2   3 
ATOM      3  CG  LEU A  50       8.727  12.295  29.523  1.00 
13.36    -0.020 C  
ATOM      4  CD2 LEU A  50      10.076  12.999  29.587  1.00 
11.01     0.009 C  
ATOM      5  CD1 LEU A  50       7.673  13.063  30.296  1.00 
11.28     0.009 C  
ENDBRANCH   2   3 
ENDBRANCH   1   2 
END_RES LEU A  50 
BEGIN_RES LEU A  53 
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REMARK  1 active torsions: 
REMARK  status: ('A' for Active; 'I' for Inactive) 
REMARK    3  A    between atoms: CA   and  CB   
REMARK       I    between atoms: CB   and  CG   
ROOT 
ATOM      6  CA  LEU A  53      13.763   7.673  27.601  1.00 
10.12     0.177 C  
ENDROOT 
BRANCH   6   7 
ATOM      7  CB  LEU A  53      13.561   9.190  27.484  1.00 
10.09     0.038 C  
ATOM      8  CG  LEU A  53      14.846  10.013  27.342  1.00 
14.17    -0.020 C  
ATOM      9  CD2 LEU A  53      14.500  11.493  27.234  1.00 
15.42     0.009 C  
ATOM     10  CD1 LEU A  53      15.623   9.551  26.114  1.00 
13.92     0.009 C  
ENDBRANCH   6   7 
END_RES LEU A  53 
BEGIN_RES ILE A  57 
REMARK  1 active torsions: 
REMARK  status: ('A' for Active; 'I' for Inactive) 
REMARK       I    between atoms: CA   and  CB   
REMARK    4  A    between atoms: CB   and  CG1  
ROOT 
ATOM     11  CB  ILE A  57      18.694   7.357  31.036  1.00  
8.44     0.013 C  
ENDROOT 
BRANCH  11  12 
ATOM     12  CG1 ILE A  57      18.441   8.505  30.053  1.00 
10.51     0.002 C  
ATOM     13  CD1 ILE A  57      17.724   9.691  30.650  1.00 
10.63     0.005 C  
ENDBRANCH  11  12 
END_RES ILE A  57 
BEGIN_RES HIS A  69 
REMARK  2 active torsions: 
REMARK  status: ('A' for Active; 'I' for Inactive) 
REMARK    5  A    between atoms: CA   and  CB   
REMARK    6  A    between atoms: CB   and  CG   
ROOT 
ATOM     14  CA  HIS A  69      19.751  12.132  39.250  1.00 
10.97     0.182 C  
ENDROOT 
BRANCH  14  15 
ATOM     15  CB  HIS A  69      19.087  13.136  40.206  1.00 
13.11     0.093 C  
BRANCH  15  16 
ATOM     16  CG  HIS A  69      20.025  14.161  40.764  1.00 
13.45     0.030 A  
ATOM     17  CD2 HIS A  69      20.759  14.170  41.902  1.00 
17.53     0.143 A  
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ATOM     18  NE2 HIS A  69      21.452  15.357  41.926  1.00 
17.19    -0.254 NA 
ATOM     19  CE1 HIS A  69      21.155  16.050  40.842  1.00 
18.20     0.207 A  
ATOM     20  ND1 HIS A  69      20.296  15.350  40.123  1.00 
16.07    -0.353 N  
ATOM     21  HD1 HIS A  69      19.900  15.641  39.241  1.00  
0.00     0.166 HD 
ENDBRANCH  15  16 
ENDBRANCH  14  15 
END_RES HIS A  69 
BEGIN_RES VAL A  89 
REMARK  1 active torsions: 
REMARK  status: ('A' for Active; 'I' for Inactive) 
REMARK    7  A    between atoms: CA   and  CB   
ROOT 
ATOM     22  CA  VAL A  89      16.027  14.124  35.948  1.00 
10.52     0.180 C  
ENDROOT 
BRANCH  22  23 
ATOM     23  CB  VAL A  89      15.913  12.637  36.388  1.00 
10.21     0.009 C  
ATOM     24  CG1 VAL A  89      16.875  11.774  35.569  1.00 
11.26     0.012 C  
ATOM     25  CG2 VAL A  89      16.187  12.499  37.875  1.00 
10.50     0.012 C  
ENDBRANCH  22  23 
END_RES VAL A  89 
BEGIN_RES HIS A  92 
REMARK  2 active torsions: 
REMARK  status: ('A' for Active; 'I' for Inactive) 
REMARK    8  A    between atoms: CA   and  CB   
REMARK    9  A    between atoms: CB   and  CG   
ROOT 
ATOM     26  CA  HIS A  92      11.157  18.396  34.121  1.00 
10.57     0.182 C  
ENDROOT 
BRANCH  26  27 
ATOM     27  CB  HIS A  92       9.916  18.053  34.950  1.00 
11.85     0.095 C  
BRANCH  27  28 
ATOM     28  CG  HIS A  92      10.067  16.802  35.761  1.00 
11.71     0.053 A  
ATOM     29  ND1 HIS A  92       8.991  16.050  36.181  1.00 
13.27    -0.247 NA 
ATOM     30  CE1 HIS A  92       9.426  15.005  36.863  1.00 
13.40     0.207 A  
ATOM     31  NE2 HIS A  92      10.745  15.054  36.903  1.00 
14.08    -0.359 N  
ATOM     32  HE2 HIS A  92      11.344  14.381  37.360  1.00  
0.00     0.166 HD 
ATOM     33  CD2 HIS A  92      11.171  16.168  36.223  1.00 
 100 
 
13.21     0.116 A  
ENDBRANCH  27  28 
ENDBRANCH  26  27 
END_RES HIS A  92 
BEGIN_RES TYR A  96 
REMARK  3 active torsions: 
REMARK  status: ('A' for Active; 'I' for Inactive) 
REMARK   10  A    between atoms: CA   and  CB   
REMARK   11  A    between atoms: CB   and  CG   
REMARK   12  A    between atoms: CZ   and  OH   
ROOT 
ATOM     34  CA  TYR A  96       9.955  18.557  28.206  1.00  
9.98     0.180 C  
ENDROOT 
BRANCH  34  35 
ATOM     35  CB  TYR A  96       8.759  19.165  28.947  1.00 
10.95     0.073 C  
BRANCH  35  36 
ATOM     36  CG  TYR A  96       7.758  18.146  29.436  1.00 
10.20    -0.056 A  
ATOM     37  CD2 TYR A  96       6.561  17.944  28.758  1.00 
12.34     0.010 A  
ATOM     38  CE2 TYR A  96       5.646  16.998  29.188  1.00 
10.72     0.037 A  
ATOM     39  CZ  TYR A  96       5.924  16.244  30.307  1.00 
12.51     0.065 A  
ATOM     40  CE1 TYR A  96       7.105  16.426  31.000  1.00 
12.43     0.037 A  
ATOM     41  CD1 TYR A  96       8.014  17.373  30.562  1.00 
10.18     0.010 A  
BRANCH  39  42 
ATOM     42  OH  TYR A  96       5.018  15.302  30.733  1.00 
14.86    -0.361 OA 
ATOM     43  HH  TYR A  96       4.184  15.730  30.939  1.00  
0.00     0.217 HD 
ENDBRANCH  39  42 
ENDBRANCH  35  36 
ENDBRANCH  34  35 
END_RES TYR A  96 
 
Grid Parameter File 
 
npts 60 62 62                        # num.grid points in xyz 
gridfld 4ipf_rigid.maps.fld          # grid_data_file 
spacing 0.375                        # spacing(A) 
receptor_types A C NA OA N SA HD     # receptor atom types 
ligand_types A C Cl NA OA N S HD     # ligand atom types 
receptor 4ipf_rigid.pdbqt            # macromolecule 
gridcenter 13.988 9.562 35.855       # xyz-coordinates or auto 
smooth 0.5                           # store minimum energy w/in 
rad(A) 
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map 4ipf_rigid.A.map                 # atom-specific affinity map 
map 4ipf_rigid.C.map                 # atom-specific affinity map 
map 4ipf_rigid.Cl.map                # atom-specific affinity map 
map 4ipf_rigid.NA.map                # atom-specific affinity map 
map 4ipf_rigid.OA.map                # atom-specific affinity map 
map 4ipf_rigid.N.map                 # atom-specific affinity map 
map 4ipf_rigid.S.map                 # atom-specific affinity map 
map 4ipf_rigid.HD.map                # atom-specific affinity map 
elecmap 4ipf_rigid.e.map             # electrostatic potential 
map 
dsolvmap 4ipf_rigid.d.map              # desolvation potential 
map 
dielectric -0.1465                   # <0, AD4 distance-
dep.diel;>0, constant 
 
Docking Parameter File 
autodock_parameter_version 4.2       # used by autodock to 
validate parameter set 
outlev 1                             # diagnostic output level 
intelec                              # calculate internal 
electrostatics 
seed pid time                        # seeds for random generator 
ligand_types A C Cl NA OA N S HD     # atoms types in ligand 
fld 4ipf_rigid.maps.fld              # grid_data_file 
map 4ipf_rigid.A.map                 # atom-specific affinity map 
map 4ipf_rigid.C.map                 # atom-specific affinity map 
map 4ipf_rigid.Cl.map                # atom-specific affinity map 
map 4ipf_rigid.NA.map                # atom-specific affinity map 
map 4ipf_rigid.OA.map                # atom-specific affinity map 
map 4ipf_rigid.N.map                 # atom-specific affinity map 
map 4ipf_rigid.S.map                 # atom-specific affinity map 
map 4ipf_rigid.HD.map                # atom-specific affinity map 
elecmap 4ipf_rigid.e.map             # electrostatics map 
desolvmap 4ipf_rigid.d.map           # desolvation map 
move 4ipf_lig.pdbqt                  # small molecule 
flexres 4ipf_flex.pdbqt                  # file containing 
flexible residues 
about 13.5638 8.4251 37.0794         # small molecule center 
tran0 random                         # initial coordinates/A or 
random 
quaternion0 random                   # initial orientation 
dihe0 random                         # initial dihedrals 
(relative) or random 
torsdof 10                            # torsional degrees of 
freedom 
rmstol 2.0                           # cluster_tolerance/A 
extnrg 1000.0                        # external grid energy 
e0max 0.0 10000                      # max initial energy; max 
number of retries 
ga_pop_size 150                      # number of individuals in 
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population 
ga_num_evals 20000000                # maximum number of energy 
evaluations 
ga_num_generations 27000             # maximum number of 
generations 
ga_elitism 1                         # number of top individuals 
to survive to next generation 
ga_mutation_rate 0.02                # rate of gene mutation 
ga_crossover_rate 0.8                # rate of crossover 
ga_window_size 10                    #  
ga_cauchy_alpha 0.0                  # Alpha parameter of Cauchy 
distribution 
ga_cauchy_beta 1.0                   # Beta parameter Cauchy 
distribution 
set_ga                               # set the above parameters 
for GA or LGA 
sw_max_its 300                       # iterations of Solis & Wets 
local search 
sw_max_succ 4                        # consecutive successes 
before changing rho 
sw_max_fail 4                        # consecutive failures 
before changing rho 
sw_rho 1.0                           # size of local search space 
to sample 
sw_lb_rho 0.01                       # lower bound on rho 
ls_search_freq 0.06                  # probability of performing 
local search on individual 
set_psw1                             # set the above pseudo-Solis 
& Wets parameters 
unbound_model bound                  # state of unbound ligand 
ga_run 100                            # do this many hybrid GA-LS 
runs 
analysis                             # perform a ranked cluster 
analysis 
 
Vina Configuration File 
receptor = 4ipf_rigid.pdbqt 
flex = 4ipf_flex.pdbqt 
ligand = 4ipf_lig.pdbqt 
 
out = out.4ipf.pdbqt 
 
center_x = 13.988 
center_y = 9.562 
center_z = 35.855 
 
size_x = 27 
size_y = 27 
size_z = 27 
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exhaustiveness = 12 
 
Ligand Input File 
REMARK  10 active torsions: 
REMARK  status: ('A' for Active; 'I' for Inactive) 
REMARK       I    between atoms: N1_1  and  C10_23  
REMARK    1  A    between atoms: C5_2  and  C51_4  
REMARK    2  A    between atoms: C4_5  and  C41_7  
REMARK    3  A    between atoms: C2_9  and  C21_10  
REMARK       I    between atoms: C10_23  and  N10_25  
REMARK    4  A    between atoms: N12_28  and  C15_49  
REMARK    5  A    between atoms: C24_33  and  C30_34  
REMARK    6  A    between atoms: C26_38  and  O27_39  
REMARK    7  A    between atoms: O27_39  and  C28_40  
REMARK    8  A    between atoms: C16_43  and  C17_44  
REMARK    9  A    between atoms: C16_43  and  C15_49  
REMARK   10  A    between atoms: C17_44  and  S17_45  
ROOT 
ATOM      1  N1  1F0 A          12.567   8.335  35.668  0.00  
0.00    -0.226 N  
ATOM      2  C5  1F0 A          11.695   9.079  34.712  0.00  
0.00     0.096 C  
ATOM      3  C57 1F0 A          10.610   8.150  34.083  0.00  
0.00     0.041 C  
ATOM      4  C4  1F0 A          11.040  10.172  35.653  0.00  
0.00     0.111 C  
ATOM      5  C47 1F0 A           9.767   9.671  36.400  0.00  
0.00     0.045 C  
ATOM      6  N3  1F0 A          12.042  10.275  36.747  0.00  
0.00    -0.255 NA 
ATOM      7  C2  1F0 A          12.808   9.256  36.742  0.00  
0.00     0.134 C  
ATOM      8  C10 1F0 A          12.978   7.059  35.425  0.00  
0.00     0.310 C  
ATOM      9  O10 1F0 A          13.183   6.667  34.294  0.00  
0.00    -0.253 OA 
ATOM     10  N10 1F0 A          13.169   6.220  36.487  0.00  
0.00    -0.275 N  
ATOM     11  C14 1F0 A          13.880   4.941  36.289  0.00  
0.00     0.160 C  
ATOM     12  C13 1F0 A          14.711   4.566  37.526  0.00  
0.00     0.148 C  
ATOM     13  N12 1F0 A          13.928   4.572  38.814  0.00  
0.00     0.249 N  
ATOM     14  C12 1F0 A          13.249   5.917  38.965  0.00  
0.00     0.148 C  
ATOM     15  C11 1F0 A          12.377   6.267  37.741  0.00  
0.00     0.160 C  
ATOM     16 2HN1 1F0 A          13.190   3.846  38.764  0.00  
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0.00     0.200 HD 
ENDROOT 
BRANCH   7  17 
ATOM     17  C21 1F0 A          13.874   9.070  37.782  0.00  
0.00     0.045 A  
ATOM     18  C22 1F0 A          13.559   9.415  39.098  0.00  
0.00     0.015 A  
ATOM     19  C23 1F0 A          14.477   9.252  40.134  0.00  
0.00     0.005 A  
ATOM     20  C24 1F0 A          15.758   8.750  39.887  0.00  
0.00    -0.040 A  
ATOM     21  C25 1F0 A          16.098   8.462  38.559  0.00  
0.00     0.038 A  
ATOM     22  C26 1F0 A          15.172   8.596  37.515  0.00  
0.00     0.086 A  
BRANCH  20  23 
ATOM     23  C30 1F0 A          16.797   8.569  41.017  0.00  
0.00    -0.013 C  
ATOM     24  C33 1F0 A          17.792   9.754  40.991  0.00  
0.00     0.016 C  
ATOM     25  C31 1F0 A          17.589   7.246  40.846  0.00  
0.00     0.016 C  
ATOM     26  C32 1F0 A          16.163   8.516  42.435  0.00  
0.00     0.016 C  
ENDBRANCH  20  23 
BRANCH  22  27 
ATOM     27  O27 1F0 A          15.527   8.251  36.223  0.00  
0.00    -0.346 OA 
BRANCH  27  28 
ATOM     28  C28 1F0 A          16.855   7.848  35.817  0.00  
0.00     0.164 C  
ATOM     29  C29 1F0 A          16.837   7.543  34.313  0.00  
0.00     0.035 C  
ENDBRANCH  27  28 
ENDBRANCH  22  27 
ENDBRANCH   7  17 
BRANCH   2  30 
ATOM     30  C51 1F0 A          12.522   9.750  33.579  0.00  
0.00    -0.021 A  
ATOM     31  C56 1F0 A          13.883  10.041  33.743  0.00  
0.00     0.007 A  
ATOM     32  C55 1F0 A          14.610  10.691  32.750  0.00  
0.00     0.021 A  
ATOM     33  C54 1F0 A          13.989  11.076  31.567  0.00  
0.00     0.041 A  
ATOM     34 CL5  1F0 A          14.895  11.887  30.337  0.00  
0.00    -0.084 Cl 
ATOM     35  C53 1F0 A          12.635  10.815  31.385  0.00  
0.00     0.021 A  
ATOM     36  C52 1F0 A          11.910  10.159  32.380  0.00  
0.00     0.007 A  
ENDBRANCH   2  30 
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BRANCH   4  37 
ATOM     37  C41 1F0 A          10.778  11.519  34.951  0.00  
0.00    -0.018 A  
ATOM     38  C42 1F0 A           9.556  11.785  34.315  0.00  
0.00     0.008 A  
ATOM     39  C43 1F0 A           9.354  12.981  33.629  0.00  
0.00     0.021 A  
ATOM     40  C44 1F0 A          10.379  13.922  33.552  0.00  
0.00     0.041 A  
ATOM     41 CL4  1F0 A          10.137  15.393  32.673  0.00  
0.00    -0.084 Cl 
ATOM     42  C45 1F0 A          11.600  13.672  34.172  0.00  
0.00     0.021 A  
ATOM     43  C46 1F0 A          11.794  12.482  34.871  0.00  
0.00     0.008 A  
ENDBRANCH   4  37 
BRANCH  13  44 
ATOM     44  C15 1F0 A          14.886   4.237  39.941  0.00  
0.00     0.141 C  
BRANCH  44  45 
ATOM     45  C16 1F0 A          14.280   4.213  41.357  0.00  
0.00     0.176 C  
BRANCH  45  46 
ATOM     46  C17 1F0 A          15.260   3.679  42.435  0.00  
0.00     0.530 C  
BRANCH  46  47 
ATOM     47  S17 1F0 A          14.568   4.133  43.989  0.00  
0.00    -0.280 S  
ATOM     48  C19 1F0 A          15.491   3.473  45.350  0.00  
0.00     0.666 C  
ATOM     49  O17 1F0 A          13.278   3.527  44.023  0.00  
0.00    -0.525 OA 
ATOM     50  O18 1F0 A          14.693   5.552  44.050  0.00  
0.00    -0.525 OA 
ENDBRANCH  46  47 
ENDBRANCH  45  46 
ENDBRANCH  44  45 
ENDBRANCH  13  44 
TORSDOF 10 
 
Grid Parameter File 
 
npts 60 62 62                        # num.grid points in xyz 
gridfld 4ipf_rigid.maps.fld          # grid_data_file 
spacing 0.375                        # spacing(A) 
receptor_types A C HD N NA OA SA     # receptor atom types 
ligand_types A C Cl NA OA N S HD     # ligand atom types 
receptor 4ipf_rigid.pdbqt            # macromolecule 
gridcenter 13.988 9.562 35.855       # xyz-coordinates or auto 
smooth 0.5                           # store minimum energy w/in 
rad(A) 
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map 4ipf_rigid.A.map                 # atom-specific affinity map 
map 4ipf_rigid.C.map                 # atom-specific affinity map 
map 4ipf_rigid.Cl.map                # atom-specific affinity map 
map 4ipf_rigid.NA.map                # atom-specific affinity map 
map 4ipf_rigid.OA.map                # atom-specific affinity map 
map 4ipf_rigid.N.map                 # atom-specific affinity map 
map 4ipf_rigid.S.map                 # atom-specific affinity map 
map 4ipf_rigid.HD.map                # atom-specific affinity map 
elecmap 4ipf_rigid.e.map             # electrostatic potential 
map 
dsolvmap 4ipf_rigid.d.map              # desolvation potential 
map 
dielectric -0.1465                   # <0, AD4 distance-
dep.diel;>0, constant 
 
Docking Parameter File 
 
autodock_parameter_version 4.2       # used by autodock to 
validate parameter set 
outlev 1                             # diagnostic output level 
intelec                              # calculate internal 
electrostatics 
seed pid time                        # seeds for random generator 
ligand_types A C Cl NA OA N S HD     # atoms types in ligand 
fld 4ipf_rigid.maps.fld              # grid_data_file 
map 4ipf_rigid.A.map                 # atom-specific affinity map 
map 4ipf_rigid.C.map                 # atom-specific affinity map 
map 4ipf_rigid.Cl.map                # atom-specific affinity map 
map 4ipf_rigid.NA.map                # atom-specific affinity map 
map 4ipf_rigid.OA.map                # atom-specific affinity map 
map 4ipf_rigid.N.map                 # atom-specific affinity map 
map 4ipf_rigid.S.map                 # atom-specific affinity map 
map 4ipf_rigid.HD.map                # atom-specific affinity map 
elecmap 4ipf_rigid.e.map             # electrostatics map 
desolvmap 4ipf_rigid.d.map           # desolvation map 
move 4ipf_lig.pdbqt                  # small molecule 
about 13.5638 8.4251 37.0794         # small molecule center 
tran0 random                         # initial coordinates/A or 
random 
quaternion0 random                   # initial orientation 
dihe0 random                         # initial dihedrals 
(relative) or random 
torsdof 10                            # torsional degrees of 
freedom 
rmstol 2.0                           # cluster_tolerance/A 
extnrg 1000.0                        # external grid energy 
e0max 0.0 10000                      # max initial energy; max 
number of retries 
ga_pop_size 150                      # number of individuals in 
population 
ga_num_evals 20000000                 # maximum number of energy 
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evaluations 
ga_num_generations 27000             # maximum number of 
generations 
ga_elitism 1                         # number of top individuals 
to survive to next generation 
ga_mutation_rate 0.02                # rate of gene mutation 
ga_crossover_rate 0.8                # rate of crossover 
ga_window_size 10                    #  
ga_cauchy_alpha 0.0                  # Alpha parameter of Cauchy 
distribution 
ga_cauchy_beta 1.0                   # Beta parameter Cauchy 
distribution 
set_ga                               # set the above parameters 
for GA or LGA 
sw_max_its 300                       # iterations of Solis & Wets 
local search 
sw_max_succ 4                        # consecutive successes 
before changing rho 
sw_max_fail 4                        # consecutive failures 
before changing rho 
sw_rho 1.0                           # size of local search space 
to sample 
sw_lb_rho 0.01                       # lower bound on rho 
ls_search_freq 0.06                  # probability of performing 
local search on individual 
set_psw1                             # set the above pseudo-Solis 
& Wets parameters 
unbound_model bound                  # state of unbound ligand 
ga_run 100                            # do this many hybrid GA-LS 
runs 
analysis                             # perform a ranked cluster 
analysis 
 
Vina Configuration File 
 
receptor = 4ipf.rec.pdbqt 
ligand = 4ipf.lig.pdbqt 
 
out = out.4ipf.pdbqt 
 
center_x = 13.988 
center_y = 9.562 
center_z = 35.855 
 
size_x = 27 
size_y = 27 
size_z = 27 
 
exhaustiveness = 12 
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Ligand Input File 
REMARK  6 active torsions: 
REMARK  status: ('A' for Active; 'I' for Inactive) 
REMARK       I    between atoms: N1_1  and  C10_23  
REMARK    1  A    between atoms: C5_2  and  C51_4  
REMARK    2  A    between atoms: C4_5  and  C41_7  
REMARK    3  A    between atoms: C2_9  and  C21_10  
REMARK       I    between atoms: C10_23  and  N10_25  
REMARK       I    between atoms: N12_28  and  C15_49  
REMARK    4  A    between atoms: C24_33  and  C30_34  
REMARK       I    between atoms: C26_38  and  O27_39  
REMARK       I    between atoms: O27_39  and  C28_40  
REMARK    5  A    between atoms: C16_43  and  C17_44  
REMARK       I    between atoms: C16_43  and  C15_49  
REMARK    6  A    between atoms: C17_44  and  S17_45  
ROOT 
ATOM      1  N1  1F0 A          12.593   8.448  35.680  0.00  
0.00    -0.226 N  
ATOM      2  C5  1F0 A          11.693   9.088  34.737  0.00  
0.00     0.096 C  
ATOM      3  C57 1F0 A          10.648   8.109  34.173  0.00  
0.00     0.041 C  
ATOM      4  C4  1F0 A          11.040  10.162  35.660  0.00  
0.00     0.111 C  
ATOM      5  C47 1F0 A           9.715   9.646  36.222  0.00  
0.00     0.045 C  
ATOM      6  N3  1F0 A          11.997  10.317  36.772  0.00  
0.00    -0.255 NA 
ATOM      7  C2  1F0 A          12.817   9.323  36.800  0.00  
0.00     0.134 C  
ATOM      8  C10 1F0 A          13.066   7.097  35.478  0.00  
0.00     0.310 C  
ATOM      9  O10 1F0 A          13.331   6.708  34.334  0.00  
0.00    -0.253 OA 
ATOM     10  N10 1F0 A          13.241   6.247  36.580  0.00  
0.00    -0.275 N  
ATOM     11  C14 1F0 A          13.894   4.961  36.360  0.00  
0.00     0.160 C  
ATOM     12  C13 1F0 A          14.773   4.636  37.554  0.00  
0.00     0.148 C  
ATOM     13  N12 1F0 A          13.986   4.650  38.811  0.00  
0.00     0.249 N  
ATOM     14  C12 1F0 A          13.338   5.980  39.031  0.00  
0.00     0.148 C  
ATOM     15  C11 1F0 A          12.468   6.395  37.819  0.00  
0.00     0.160 C  
ATOM     16  C16 1F0 A          14.105   4.266  41.285  0.00  
0.00     0.176 C  
ATOM     17  C15 1F0 A          14.837   4.223  39.942  0.00  
0.00     0.141 C  
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ATOM     18 2HN1 1F0 A          13.248   3.967  38.713  0.00  
0.00     0.200 HD 
ENDROOT 
BRANCH   2  19 
ATOM     19  C51 1F0 A          12.519   9.725  33.633  0.00  
0.00    -0.021 A  
ATOM     20  C56 1F0 A          13.895   9.911  33.814  0.00  
0.00     0.007 A  
ATOM     21  C55 1F0 A          14.651  10.585  32.847  0.00  
0.00     0.021 A  
ATOM     22  C54 1F0 A          14.023  11.069  31.699  0.00  
0.00     0.041 A  
ATOM     23 CL5  1F0 A          14.949  12.020  30.533  0.00  
0.00    -0.084 Cl 
ATOM     24  C53 1F0 A          12.664  10.823  31.476  0.00  
0.00     0.021 A  
ATOM     25  C52 1F0 A          11.913  10.151  32.443  0.00  
0.00     0.007 A  
ENDBRANCH   2  19 
BRANCH   7  26 
ATOM     26  C21 1F0 A          13.848   9.094  37.832  0.00  
0.00     0.045 A  
ATOM     27  C22 1F0 A          13.564   9.406  39.163  0.00  
0.00     0.015 A  
ATOM     28  C23 1F0 A          14.532   9.237  40.156  0.00  
0.00     0.005 A  
ATOM     29  C24 1F0 A          15.800   8.743  39.831  0.00  
0.00    -0.040 A  
ATOM     30  C25 1F0 A          16.109   8.427  38.504  0.00  
0.00     0.038 A  
ATOM     31  C26 1F0 A          15.127   8.612  37.519  0.00  
0.00     0.086 A  
ATOM     32  O27 1F0 A          15.422   8.340  36.211  0.00  
0.00    -0.346 OA 
ATOM     33  C28 1F0 A          16.739   7.881  35.949  0.00  
0.00     0.164 C  
ATOM     34  C29 1F0 A          16.882   7.542  34.459  0.00  
0.00     0.035 C  
BRANCH  29  35 
ATOM     35  C30 1F0 A          16.824   8.563  40.922  0.00  
0.00    -0.013 C  
ATOM     36  C33 1F0 A          17.797   9.747  40.911  0.00  
0.00     0.016 C  
ATOM     37  C31 1F0 A          17.604   7.264  40.697  0.00  
0.00     0.016 C  
ATOM     38  C32 1F0 A          16.117   8.501  42.279  0.00  
0.00     0.016 C  
ENDBRANCH  29  35 
ENDBRANCH   7  26 
BRANCH   4  39 
ATOM     39  C41 1F0 A          10.803  11.463  34.943  0.00  
0.00    -0.018 A  
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ATOM     40  C42 1F0 A           9.543  11.722  34.394  0.00  
0.00     0.008 A  
ATOM     41  C43 1F0 A           9.314  12.907  33.701  0.00  
0.00     0.021 A  
ATOM     42  C44 1F0 A          10.353  13.825  33.559  0.00  
0.00     0.041 A  
ATOM     43 CL4  1F0 A          10.088  15.305  32.647  0.00  
0.00    -0.084 Cl 
ATOM     44  C45 1F0 A          11.608  13.583  34.122  0.00  
0.00     0.021 A  
ATOM     45  C46 1F0 A          11.828  12.400  34.819  0.00  
0.00     0.008 A  
ENDBRANCH   4  39 
BRANCH  16  46 
ATOM     46  C17 1F0 A          15.068   3.786  42.382  0.00  
0.00     0.530 C  
BRANCH  46  47 
ATOM     47  S17 1F0 A          14.470   4.217  43.996  0.00  
0.00    -0.280 S  
ATOM     48  C19 1F0 A          15.569   3.418  45.143  0.00  
0.00     0.666 C  
ATOM     49  O17 1F0 A          13.138   3.656  44.163  0.00  
0.00    -0.525 OA 
ATOM     50  O18 1F0 A          14.594   5.666  44.158  0.00  
0.00    -0.525 OA 
ENDBRANCH  46  47 
ENDBRANCH  16  46 
TORSDOF 10 
 
Flexible Residue File 
BEGIN_RES LEU A  50 
REMARK  2 active torsions: 
REMARK  status: ('A' for Active; 'I' for Inactive) 
REMARK    1  A    between atoms: CA   and  CB   
REMARK    2  A    between atoms: CB   and  CG   
ROOT 
ATOM      1  CA  LEU A  50       9.533   9.929  29.079  1.00 
10.27     0.186 C  
ENDROOT 
BRANCH   1   2 
ATOM      2  CB  LEU A  50       8.870  10.875  30.081  1.00 
10.02     0.034 C  
BRANCH   2   3 
ATOM      3  CG  LEU A  50       8.727  12.295  29.523  1.00 
13.36     0.002 C  
ATOM      4  CD1 LEU A  50       7.673  13.063  30.296  1.00 
11.28     0.000 C  
ATOM      5  CD2 LEU A  50      10.076  12.999  29.587  1.00 
11.01     0.000 C  
ENDBRANCH   2   3 
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ENDBRANCH   1   2 
END_RES LEU A  50 
BEGIN_RES LEU A  53 
REMARK  2 active torsions: 
REMARK  status: ('A' for Active; 'I' for Inactive) 
REMARK    3  A    between atoms: CA   and  CB   
REMARK    4  A    between atoms: CB   and  CG   
ROOT 
ATOM      6  CA  LEU A  53      13.763   7.673  27.601  1.00 
10.12     0.186 C  
ENDROOT 
BRANCH   6   7 
ATOM      7  CB  LEU A  53      13.561   9.190  27.484  1.00 
10.09     0.034 C  
BRANCH   7   8 
ATOM      8  CG  LEU A  53      14.846  10.013  27.342  1.00 
14.17     0.002 C  
ATOM      9  CD2 LEU A  53      14.500  11.493  27.234  1.00 
15.42     0.000 C  
ATOM     10  CD1 LEU A  53      15.623   9.551  26.114  1.00 
13.92     0.000 C  
ENDBRANCH   7   8 
ENDBRANCH   6   7 
END_RES LEU A  53 
BEGIN_RES HIS A  69 
REMARK  2 active torsions: 
REMARK  status: ('A' for Active; 'I' for Inactive) 
REMARK    5  A    between atoms: CA   and  CB   
REMARK    6  A    between atoms: CB   and  CG   
ROOT 
ATOM     11  CA  HIS A  69      19.751  12.132  39.250  1.00 
10.97     0.192 C  
ENDROOT 
BRANCH  11  12 
ATOM     12  CB  HIS A  69      19.087  13.136  40.206  1.00 
13.11     0.082 C  
BRANCH  12  13 
ATOM     13  CG  HIS A  69      20.025  14.161  40.764  1.00 
13.45     0.082 A  
ATOM     14  ND1 HIS A  69      20.296  15.350  40.123  1.00 
16.07    -0.227 NA 
ATOM     15  CE1 HIS A  69      21.155  16.050  40.842  1.00 
18.20     0.199 A  
ATOM     16  NE2 HIS A  69      21.452  15.357  41.926  1.00 
17.19    -0.221 NA 
ATOM     17  CD2 HIS A  69      20.759  14.170  41.902  1.00 
17.53     0.116 A  
ENDBRANCH  12  13 
ENDBRANCH  11  12 
END_RES HIS A  69 
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Grid Parameter File 
npts 60 62 62                        # num.grid points in xyz 
gridfld 4ipf_rigid.maps.fld          # grid_data_file 
spacing 0.375                        # spacing(A) 
receptor_types A C N NA OA SA HD       # receptor atom types 
ligand_types A C Cl NA OA N S HD     # ligand atom types 
receptor 4ipf_rigid.pdbqt            # macromolecule 
gridcenter 13.988 9.562 35.855       # xyz-coordinates or auto 
smooth 0.5                           # store minimum energy w/in 
rad(A) 
map 4ipf_rigid.A.map                 # atom-specific affinity map 
map 4ipf_rigid.C.map                 # atom-specific affinity map 
map 4ipf_rigid.Cl.map                # atom-specific affinity map 
map 4ipf_rigid.NA.map                # atom-specific affinity map 
map 4ipf_rigid.OA.map                # atom-specific affinity map 
map 4ipf_rigid.N.map                 # atom-specific affinity map 
map 4ipf_rigid.S.map                 # atom-specific affinity map 
map 4ipf_rigid.HD.map                # atom-specific affinity map 
elecmap 4ipf_rigid.e.map             # electrostatic potential 
map 
dsolvmap 4ipf_rigid.d.map              # desolvation potential 
map 
dielectric -0.1465                   # <0, AD4 distance-
dep.diel;>0, constant 
 
Docking Parameter File 
autodock_parameter_version 4.2       # used by autodock to 
validate parameter set 
outlev 1                             # diagnostic output level 
intelec                              # calculate internal 
electrostatics 
seed pid time                        # seeds for random generator 
ligand_types A C Cl NA OA N S HD     # atoms types in ligand 
fld 4ipf_rigid.maps.fld              # grid_data_file 
map 4ipf_rigid.A.map                 # atom-specific affinity map 
map 4ipf_rigid.C.map                 # atom-specific affinity map 
map 4ipf_rigid.Cl.map                # atom-specific affinity map 
map 4ipf_rigid.NA.map                # atom-specific affinity map 
map 4ipf_rigid.OA.map                # atom-specific affinity map 
map 4ipf_rigid.N.map                 # atom-specific affinity map 
map 4ipf_rigid.S.map                 # atom-specific affinity map 
map 4ipf_rigid.HD.map                # atom-specific affinity map 
elecmap 4ipf_rigid.e.map             # electrostatics map 
desolvmap 4ipf_rigid.d.map           # desolvation map 
move 4ipf_lig.pdbqt                  # small molecule 
flexres 4ipf_flex.pdbqt                  # file containing 
flexible residues 
about 13.5629 8.4362 37.0971         # small molecule center 
tran0 random                         # initial coordinates/A or 
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random 
quaternion0 random                   # initial orientation 
dihe0 random                         # initial dihedrals 
(relative) or random 
torsdof 10                            # torsional degrees of 
freedom 
rmstol 2.0                           # cluster_tolerance/A 
extnrg 1000.0                        # external grid energy 
e0max 0.0 10000                      # max initial energy; max 
number of retries 
ga_pop_size 150                      # number of individuals in 
population 
ga_num_evals 20000000                 # maximum number of energy 
evaluations 
ga_num_generations 27000             # maximum number of 
generations 
ga_elitism 1                         # number of top individuals 
to survive to next generation 
ga_mutation_rate 0.02                # rate of gene mutation 
ga_crossover_rate 0.8                # rate of crossover 
ga_window_size 10                    #  
ga_cauchy_alpha 0.0                  # Alpha parameter of Cauchy 
distribution 
ga_cauchy_beta 1.0                   # Beta parameter Cauchy 
distribution 
set_ga                               # set the above parameters 
for GA or LGA 
sw_max_its 300                       # iterations of Solis & Wets 
local search 
sw_max_succ 4                        # consecutive successes 
before changing rho 
sw_max_fail 4                        # consecutive failures 
before changing rho 
sw_rho 1.0                           # size of local search space 
to sample 
sw_lb_rho 0.01                       # lower bound on rho 
ls_search_freq 0.06                  # probability of performing 
local search on individual 
set_psw1                             # set the above pseudo-Solis 
& Wets parameters 
unbound_model bound                  # state of unbound ligand 
ga_run 100                            # do this many hybrid GA-LS 
runs 
analysis                             # perform a ranked cluster 
analysis 
 
Vina Configuration File 
receptor = 4ipf_rigid.pdbqt 
flex = 4ipf_flex.pdbqt 
ligand = 4ipf_lig.pdbqt 
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out = out.4ipf.pdbqt 
 
center_x = 13.988 
center_y = 9.562 
center_z = 35.855 
 
size_x = 27 
size_y = 27 
size_z = 27 
 
exhaustiveness = 12 
 
Ligand Input File 
REMARK  0 active torsions: 
REMARK  status: ('A' for Active; 'I' for Inactive) 
REMARK       I    between atoms: C1_1  and  C10_2  
REMARK       I    between atoms: C10_2  and  N11_3  
REMARK       I    between atoms: N11_3  and  C12_4  
REMARK       I    between atoms: C12_4  and  C13_5  
REMARK       I    between atoms: C13_5  and  C14_6  
REMARK       I    between atoms: C14_6  and  O14_7  
REMARK       I    between atoms: C14_6  and  C15_8  
REMARK       I    between atoms: C15_8  and  O15_9  
REMARK       I    between atoms: C2_12  and  C21_13  
REMARK       I    between atoms: C3_20  and  C31_23  
REMARK       I    between atoms: C4_30  and  C41_31  
REMARK       I    between atoms: C41_31  and  C42_32  
ROOT 
ATOM      1  C1  I09 A          11.781  10.738  -1.043  0.00  
0.00     0.288 C  
ATOM      2  C10 I09 A          12.414  11.957  -0.431  0.00  
0.00     0.249 C  
ATOM      3  N11 I09 A          11.556  12.817   0.220  0.00  
0.00    -0.359 N  
ATOM      4  C12 I09 A          12.033  14.023   0.890  0.00  
0.00     0.125 C  
ATOM      5  C13 I09 A          12.241  15.149  -0.123  0.00  
0.00     0.053 C  
ATOM      6  C14 I09 A          12.646  16.423   0.616  0.00  
0.00     0.143 C  
ATOM      7  O14 I09 A          11.500  17.054   1.182  0.00  
0.00    -0.393 OA 
ATOM      8  C15 I09 A          13.403  17.385  -0.310  0.00  
0.00     0.195 C  
ATOM      9  O15 I09 A          12.564  17.825  -1.369  0.00  
0.00    -0.398 OA 
ATOM     10  O10 I09 A          13.634  12.192  -0.479  0.00  
0.00    -0.271 OA 
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ATOM     11  N1  I09 A          10.350  10.632  -0.589  0.00  
0.00    -0.055 N  
ATOM     12  C2  I09 A          12.467   9.466  -0.549  0.00  
0.00     0.088 C  
ATOM     13  C21 I09 A          13.595   9.007  -1.435  0.00  
0.00    -0.048 A  
ATOM     14  C26 I09 A          13.601   9.292  -2.802  0.00  
0.00     0.007 A  
ATOM     15  C25 I09 A          14.641   8.817  -3.613  0.00  
0.00     0.002 A  
ATOM     16  C22 I09 A          14.630   8.269  -0.877  0.00  
0.00     0.031 A  
ATOM     17  C23 I09 A          15.669   7.801  -1.685  0.00  
0.00     0.034 A  
ATOM     18 CL2  I09 A          16.985   6.894  -0.955  0.00  
0.00    -0.084 Cl 
ATOM     19  C24 I09 A          15.678   8.063  -3.063  0.00  
0.00     0.024 A  
ATOM     20  C3  I09 A          11.330   8.456  -0.438  0.00  
0.00     0.114 C  
ATOM     21  C37 I09 A          10.965   7.977  -1.780  0.00  
0.00     0.077 C  
ATOM     22  N37 I09 A          10.689   7.604  -2.820  0.00  
0.00    -0.196 NA 
ATOM     23  C31 I09 A          11.662   7.293   0.469  0.00  
0.00    -0.033 A  
ATOM     24  C32 I09 A          12.218   7.516   1.745  0.00  
0.00     0.011 A  
ATOM     25  C33 I09 A          12.538   6.429   2.561  0.00  
0.00     0.024 A  
ATOM     26  C36 I09 A          11.426   5.988   0.024  0.00  
0.00     0.011 A  
ATOM     27  C35 I09 A          11.742   4.901   0.841  0.00  
0.00     0.024 A  
ATOM     28  C34 I09 A          12.299   5.122   2.104  0.00  
0.00     0.034 A  
ATOM     29 CL3  I09 A          12.718   3.745   3.119  0.00  
0.00    -0.084 Cl 
ATOM     30  C4  I09 A          10.187   9.303   0.095  0.00  
0.00     0.215 C  
ATOM     31  C41 I09 A           8.816   8.670  -0.208  0.00  
0.00     0.043 C  
ATOM     32  C42 I09 A           7.720   9.186   0.758  0.00  
0.00    -0.049 C  
ATOM     33  C45 I09 A           7.803  10.724   0.897  0.00  
0.00     0.014 C  
ATOM     34  C44 I09 A           7.901   8.544   2.142  0.00  
0.00     0.014 C  
ATOM     35  C43 I09 A           6.336   8.796   0.210  0.00  
0.00     0.014 C  
ATOM     36  H11 I09 A          10.568  12.607   0.234  0.00  
0.00     0.162 HD 
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ATOM     37 2HN1 I09 A           9.731  10.688  -1.385  0.00  
0.00     0.278 HD 
ATOM     38 3HN1 I09 A          10.141  11.378   0.059  0.00  
0.00     0.278 HD 
ATOM     39 4HO1 I09 A          10.882  17.281   0.483  0.00  
0.00     0.210 HD 
ATOM     40 5HO1 I09 A          13.053  18.425  -1.937  0.00  
0.00     0.209 HD 
ENDROOT 
TORSDOF 11 
 
Flexible Residue File 
BEGIN_RES LEU A  50 
REMARK  2 active torsions: 
REMARK  status: ('A' for Active; 'I' for Inactive) 
REMARK    1  A    between atoms: CA   and  CB   
REMARK    2  A    between atoms: CB   and  CG   
ROOT 
ATOM      1  CA  LEU A  50      12.169   2.858  -2.898  1.00 
29.74     0.177 C  
ENDROOT 
BRANCH   1   2 
ATOM      2  CB  LEU A  50      13.101   3.947  -3.433  1.00 
28.76     0.038 C  
BRANCH   2   3 
ATOM      3  CG  LEU A  50      14.583   3.735  -3.102  1.00 
30.22    -0.020 C  
ATOM      4  CD1 LEU A  50      15.429   4.648  -3.971  1.00 
30.37     0.009 C  
ATOM      5  CD2 LEU A  50      14.833   4.003  -1.629  1.00 
24.61     0.009 C  
ENDBRANCH   2   3 
ENDBRANCH   1   2 
END_RES LEU A  50 
BEGIN_RES ILE A  57 
REMARK  2 active torsions: 
REMARK  status: ('A' for Active; 'I' for Inactive) 
REMARK    3  A    between atoms: CA   and  CB   
REMARK    4  A    between atoms: CB   and  CG1  
ROOT 
ATOM      6  CA  ILE A  57       5.611   4.348   4.893  1.00 
31.92     0.180 C  
ENDROOT 
BRANCH   6   7 
ATOM      7  CB  ILE A  57       6.798   5.276   4.579  1.00 
30.37     0.013 C  
ATOM      8  CG2 ILE A  57       6.745   6.518   5.452  1.00 
32.04     0.012 C  
BRANCH   7   9 
ATOM      9  CG1 ILE A  57       8.107   4.518   4.810  1.00 
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32.69     0.002 C  
ATOM     10  CD1 ILE A  57       9.258   5.022   3.961  1.00 
30.75     0.005 C  
ENDBRANCH   7   9 
ENDBRANCH   6   7 
END_RES ILE A  57 
BEGIN_RES VAL A  89 
REMARK  1 active torsions: 
REMARK  status: ('A' for Active; 'I' for Inactive) 
REMARK    5  A    between atoms: CA   and  CB   
ROOT 
ATOM     11  CA  VAL A  89      13.479  10.288   4.280  1.00 
30.94     0.180 C  
ENDROOT 
BRANCH  11  12 
ATOM     12  CB  VAL A  89      12.045  10.614   3.779  1.00 
27.73     0.009 C  
ATOM     13  CG1 VAL A  89      11.030   9.813   4.563  1.00 
28.65     0.012 C  
ATOM     14  CG2 VAL A  89      11.769  12.096   3.902  1.00 
29.10     0.012 C  
ENDBRANCH  11  12 
END_RES VAL A  89 
BEGIN_RES ILE A  95 
REMARK  2 active torsions: 
REMARK  status: ('A' for Active; 'I' for Inactive) 
REMARK    6  A    between atoms: CA   and  CB   
REMARK    7  A    between atoms: CB   and  CG1  
ROOT 
ATOM     15  CA  ILE A  95      18.516   4.625   3.211  1.00 
26.56     0.180 C  
ENDROOT 
BRANCH  15  16 
ATOM     16  CB  ILE A  95      17.419   5.493   2.567  1.00 
27.98     0.013 C  
ATOM     17  CG2 ILE A  95      16.365   4.619   1.878  1.00 
24.30     0.012 C  
BRANCH  16  18 
ATOM     18  CG1 ILE A  95      16.779   6.376   3.646  1.00 
27.40     0.002 C  
ATOM     19  CD1 ILE A  95      15.909   7.506   3.097  1.00 
29.20     0.005 C  
ENDBRANCH  16  18 
ENDBRANCH  15  16 
END_RES ILE A  95 
BEGIN_RES LYS A  90 
REMARK  5 active torsions: 
REMARK  status: ('A' for Active; 'I' for Inactive) 
REMARK    8  A    between atoms: CA   and  CB   
REMARK    9  A    between atoms: CB   and  CG   
REMARK   10  A    between atoms: CG   and  CD   
REMARK   11  A    between atoms: CD   and  CE   
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REMARK   12  A    between atoms: CE   and  NZ   
ROOT 
ATOM     20  CA  LYS A  90      16.135  12.789   3.183  1.00 
34.59     0.176 C  
ENDROOT 
BRANCH  20  21 
ATOM     21  CB  LYS A  90      16.176  14.231   3.703  1.00 
37.01     0.035 C  
BRANCH  21  22 
ATOM     22  CG  LYS A  90      15.016  15.094   3.270  1.00 
38.28     0.004 C  
BRANCH  22  23 
ATOM     23  CD  LYS A  90      15.117  16.472   3.909  1.00 
44.74     0.027 C  
BRANCH  23  24 
ATOM     24  CE  LYS A  90      14.329  17.506   3.125  1.00 
48.47     0.229 C  
BRANCH  24  25 
ATOM     25  NZ  LYS A  90      14.085  18.742   3.928  1.00 
52.71    -0.079 N  
ATOM     26  HZ2 LYS A  90      13.124  19.031   3.817  1.00  
0.00     0.274 HD 
ATOM     27  HZ3 LYS A  90      14.268  18.552   4.903  1.00  
0.00     0.274 HD 
ATOM     28  HZ1 LYS A  90      14.697  19.479   3.608  1.00  
0.00     0.274 HD 
ENDBRANCH  24  25 
ENDBRANCH  23  24 
ENDBRANCH  22  23 
ENDBRANCH  21  22 
ENDBRANCH  20  21 
END_RES LYS A  90 
 
Grid Parameter File 
npts 60 62 62                        # num.grid points in xyz 
gridfld 4jrg_rigid.maps.fld          # grid_data_file 
spacing 0.375                        # spacing(A) 
receptor_types A C HD N NA OA SA     # receptor atom types 
ligand_types A C Cl NA OA N HD       # ligand atom types 
receptor 4jrg_rigid.pdbqt            # macromolecule 
gridcenter 11.493 10.5 2.759         # xyz-coordinates or auto 
smooth 0.5                           # store minimum energy w/in 
rad(A) 
map 4jrg_rigid.A.map                 # atom-specific affinity map 
map 4jrg_rigid.C.map                 # atom-specific affinity map 
map 4jrg_rigid.Cl.map                # atom-specific affinity map 
map 4jrg_rigid.NA.map                # atom-specific affinity map 
map 4jrg_rigid.OA.map                # atom-specific affinity map 
map 4jrg_rigid.N.map                 # atom-specific affinity map 
map 4jrg_rigid.HD.map                # atom-specific affinity map 
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elecmap 4jrg_rigid.e.map             # electrostatic potential 
map 
dsolvmap 4jrg_rigid.d.map              # desolvation potential 
map 
dielectric -0.1465                   # <0, AD4 distance-
dep.diel;>0, constant 
 
Docking Parameter File 
autodock_parameter_version 4.2       # used by autodock to 
validate parameter set 
outlev 1                             # diagnostic output level 
intelec                              # calculate internal 
electrostatics 
seed pid time                        # seeds for random generator 
ligand_types A C Cl NA OA N HD       # atoms types in ligand 
fld 4jrg_rigid.maps.fld              # grid_data_file 
map 4jrg_rigid.A.map                 # atom-specific affinity map 
map 4jrg_rigid.C.map                 # atom-specific affinity map 
map 4jrg_rigid.Cl.map                # atom-specific affinity map 
map 4jrg_rigid.NA.map                # atom-specific affinity map 
map 4jrg_rigid.OA.map                # atom-specific affinity map 
map 4jrg_rigid.N.map                 # atom-specific affinity map 
map 4jrg_rigid.HD.map                # atom-specific affinity map 
elecmap 4jrg_rigid.e.map             # electrostatics map 
desolvmap 4jrg_rigid.d.map           # desolvation map 
move 4jrg_lig.pdbqt                  # small molecule 
flexres 4jrg_flex.pdbqt              # file containing flexible 
residues 
about 11.8028 10.3609 -0.2311        # small molecule center 
tran0 random                         # initial coordinates/A or 
random 
quaternion0 random                   # initial orientation 
dihe0 random                         # initial dihedrals 
(relative) or random 
torsdof 11                            # torsional degrees of 
freedom 
rmstol 2.0                           # cluster_tolerance/A 
extnrg 1000.0                        # external grid energy 
e0max 0.0 10000                      # max initial energy; max 
number of retries 
ga_pop_size 150                      # number of individuals in 
population 
ga_num_evals 20000000                # maximum number of energy 
evaluations 
ga_num_generations 27000             # maximum number of 
generations 
ga_elitism 1                         # number of top individuals 
to survive to next generation 
ga_mutation_rate 0.02                # rate of gene mutation 
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ga_crossover_rate 0.8                # rate of crossover 
ga_window_size 10                    #  
ga_cauchy_alpha 0.0                  # Alpha parameter of Cauchy 
distribution 
ga_cauchy_beta 1.0                   # Beta parameter Cauchy 
distribution 
set_ga                               # set the above parameters 
for GA or LGA 
sw_max_its 300                       # iterations of Solis & Wets 
local search 
sw_max_succ 4                        # consecutive successes 
before changing rho 
sw_max_fail 4                        # consecutive failures 
before changing rho 
sw_rho 1.0                           # size of local search space 
to sample 
sw_lb_rho 0.01                       # lower bound on rho 
ls_search_freq 0.06                  # probability of performing 
local search on individual 
set_psw1                             # set the above pseudo-Solis 
& Wets parameters 
unbound_model bound                  # state of unbound ligand 
ga_run 100                            # do this many hybrid GA-LS 
runs 
analysis                             # perform a ranked cluster 
analysis 
 
Vina Configuration File 
receptor = 4jrg_rigid.pdbqt 
flex = 4jrg_flex.pdbqt 
ligand = 4jrg_lig.pdbqt 
 
out = out.4jrg.pdbqt 
 
center_x = 11.493 
center_y = 10.5 
center_z = 2.759 
 
size_x = 27 
size_y = 27 
size_z = 27 
 
exhaustiveness = 12 
 
Ligand Input File 
REMARK  12 active torsions: 
REMARK  status: ('A' for Active; 'I' for Inactive) 
REMARK    1  A    between atoms: C1_1  and  C10_2  
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REMARK    2  A    between atoms: C10_2  and  N11_3  
REMARK    3  A    between atoms: N11_3  and  C12_4  
REMARK    4  A    between atoms: C12_4  and  C13_5  
REMARK    5  A    between atoms: C13_5  and  C14_6  
REMARK    6  A    between atoms: C14_6  and  O14_7  
REMARK    7  A    between atoms: C14_6  and  C15_8  
REMARK    8  A    between atoms: C15_8  and  O15_9  
REMARK    9  A    between atoms: C2_12  and  C21_13  
REMARK   10  A    between atoms: C3_20  and  C31_23  
REMARK   11  A    between atoms: C4_30  and  C41_31  
REMARK   12  A    between atoms: C41_31  and  C42_32  
ROOT 
ATOM      1  C10 I09 A          12.414  11.957  -0.431  0.00  
0.00     0.249 C  
ATOM      2  O10 I09 A          13.634  12.192  -0.479  0.00  
0.00    -0.271 OA 
ENDROOT 
BRANCH   1   3 
ATOM      3  C1  I09 A          11.781  10.738  -1.043  0.00  
0.00     0.288 C  
ATOM      4  N1  I09 A          10.350  10.632  -0.589  0.00  
0.00    -0.055 N  
ATOM      5  C4  I09 A          10.187   9.303   0.095  0.00  
0.00     0.215 C  
ATOM      6 2HN1 I09 A           9.731  10.688  -1.385  0.00  
0.00     0.278 HD 
ATOM      7 3HN1 I09 A          10.141  11.378   0.059  0.00  
0.00     0.278 HD 
ATOM      8  C3  I09 A          11.330   8.456  -0.438  0.00  
0.00     0.114 C  
ATOM      9  C2  I09 A          12.467   9.466  -0.549  0.00  
0.00     0.088 C  
ATOM     10  C37 I09 A          10.965   7.977  -1.780  0.00  
0.00     0.077 C  
ATOM     11  N37 I09 A          10.689   7.604  -2.820  0.00  
0.00    -0.196 NA 
BRANCH   5  12 
ATOM     12  C41 I09 A           8.816   8.670  -0.208  0.00  
0.00     0.043 C  
BRANCH  12  13 
ATOM     13  C42 I09 A           7.720   9.186   0.758  0.00  
0.00    -0.049 C  
ATOM     14  C45 I09 A           7.803  10.724   0.897  0.00  
0.00     0.014 C  
ATOM     15  C44 I09 A           7.901   8.544   2.142  0.00  
0.00     0.014 C  
ATOM     16  C43 I09 A           6.336   8.796   0.210  0.00  
0.00     0.014 C  
ENDBRANCH  12  13 
ENDBRANCH   5  12 
BRANCH   8  17 
ATOM     17  C31 I09 A          11.662   7.293   0.469  0.00  
 122 
 
0.00    -0.033 A  
ATOM     18  C32 I09 A          12.218   7.516   1.745  0.00  
0.00     0.011 A  
ATOM     19  C33 I09 A          12.538   6.429   2.561  0.00  
0.00     0.024 A  
ATOM     20  C34 I09 A          12.299   5.122   2.104  0.00  
0.00     0.034 A  
ATOM     21  C35 I09 A          11.742   4.901   0.841  0.00  
0.00     0.024 A  
ATOM     22 CL3  I09 A          12.718   3.745   3.119  0.00  
0.00    -0.084 Cl 
ATOM     23  C36 I09 A          11.426   5.988   0.024  0.00  
0.00     0.011 A  
ENDBRANCH   8  17 
BRANCH   9  24 
ATOM     24  C21 I09 A          13.595   9.007  -1.435  0.00  
0.00    -0.048 A  
ATOM     25  C26 I09 A          13.601   9.292  -2.802  0.00  
0.00     0.007 A  
ATOM     26  C25 I09 A          14.641   8.817  -3.613  0.00  
0.00     0.002 A  
ATOM     27  C24 I09 A          15.678   8.063  -3.063  0.00  
0.00     0.024 A  
ATOM     28  C23 I09 A          15.669   7.801  -1.685  0.00  
0.00     0.034 A  
ATOM     29  C22 I09 A          14.630   8.269  -0.877  0.00  
0.00     0.031 A  
ATOM     30 CL2  I09 A          16.985   6.894  -0.955  0.00  
0.00    -0.084 Cl 
ENDBRANCH   9  24 
ENDBRANCH   1   3 
BRANCH   1  31 
ATOM     31  N11 I09 A          11.556  12.817   0.220  0.00  
0.00    -0.359 N  
ATOM     32  H11 I09 A          10.568  12.607   0.234  0.00  
0.00     0.162 HD 
BRANCH  31  33 
ATOM     33  C12 I09 A          12.033  14.023   0.890  0.00  
0.00     0.125 C  
BRANCH  33  34 
ATOM     34  C13 I09 A          12.241  15.149  -0.123  0.00  
0.00     0.053 C  
BRANCH  34  35 
ATOM     35  C14 I09 A          12.646  16.423   0.616  0.00  
0.00     0.143 C  
BRANCH  35  36 
ATOM     36  O14 I09 A          11.500  17.054   1.182  0.00  
0.00    -0.393 OA 
ATOM     37 4HO1 I09 A          10.882  17.281   0.483  0.00  
0.00     0.210 HD 
ENDBRANCH  35  36 
BRANCH  35  38 
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ATOM     38  C15 I09 A          13.403  17.385  -0.310  0.00  
0.00     0.195 C  
BRANCH  38  39 
ATOM     39  O15 I09 A          12.564  17.825  -1.369  0.00  
0.00    -0.398 OA 
ATOM     40 5HO1 I09 A          13.053  18.425  -1.937  0.00  
0.00     0.209 HD 
ENDBRANCH  38  39 
ENDBRANCH  35  38 
ENDBRANCH  34  35 
ENDBRANCH  33  34 
ENDBRANCH  31  33 
ENDBRANCH   1  31 
TORSDOF 11 
 
Grid Parameter File 
npts 60 62 62                        # num.grid points in xyz 
gridfld 4jrg_rigid.maps.fld          # grid_data_file 
spacing 0.375                        # spacing(A) 
receptor_types A C H HD N NA OA SA   # receptor atom types 
ligand_types A C Cl NA OA N HD       # ligand atom types 
receptor 4jrg_rigid.pdbqt            # macromolecule 
gridcenter 11.493 10.5 2.759         # xyz-coordinates or auto 
smooth 0.5                           # store minimum energy w/in 
rad(A) 
map 4jrg_rigid.A.map                 # atom-specific affinity map 
map 4jrg_rigid.C.map                 # atom-specific affinity map 
map 4jrg_rigid.Cl.map                # atom-specific affinity map 
map 4jrg_rigid.NA.map                # atom-specific affinity map 
map 4jrg_rigid.OA.map                # atom-specific affinity map 
map 4jrg_rigid.N.map                 # atom-specific affinity map 
map 4jrg_rigid.HD.map                # atom-specific affinity map 
elecmap 4jrg_rigid.e.map             # electrostatic potential 
map 
dsolvmap 4jrg_rigid.d.map              # desolvation potential 
map 
dielectric -0.1465                   # <0, AD4 distance-
dep.diel;>0, constant 
 
Docking Parameter File 
 
autodock_parameter_version 4.2       # used by autodock to 
validate parameter set 
outlev 1                             # diagnostic output level 
intelec                              # calculate internal 
electrostatics 
seed pid time                        # seeds for random generator 
ligand_types A C Cl NA OA N HD       # atoms types in ligand 
fld 4jrg_rigid.maps.fld              # grid_data_file 
map 4jrg_rigid.A.map                 # atom-specific affinity map 
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map 4jrg_rigid.C.map                 # atom-specific affinity map 
map 4jrg_rigid.Cl.map                # atom-specific affinity map 
map 4jrg_rigid.NA.map                # atom-specific affinity map 
map 4jrg_rigid.OA.map                # atom-specific affinity map 
map 4jrg_rigid.N.map                 # atom-specific affinity map 
map 4jrg_rigid.HD.map                # atom-specific affinity map 
elecmap 4jrg_rigid.e.map             # electrostatics map 
desolvmap 4jrg_rigid.d.map           # desolvation map 
move 4jrg_lig.pdbqt                  # small molecule 
about 11.8028 10.3609 -0.2311        # small molecule center 
tran0 random                         # initial coordinates/A or 
random 
quaternion0 random                   # initial orientation 
dihe0 random                         # initial dihedrals 
(relative) or random 
torsdof 12                            # torsional degrees of 
freedom 
rmstol 2.0                           # cluster_tolerance/A 
extnrg 1000.0                        # external grid energy 
e0max 0.0 10000                      # max initial energy; max 
number of retries 
ga_pop_size 150                      # number of individuals in 
population 
ga_num_evals 20000000                 # maximum number of energy 
evaluations 
ga_num_generations 27000             # maximum number of 
generations 
ga_elitism 1                         # number of top individuals 
to survive to next generation 
ga_mutation_rate 0.02                # rate of gene mutation 
ga_crossover_rate 0.8                # rate of crossover 
ga_window_size 10                    #  
ga_cauchy_alpha 0.0                  # Alpha parameter of Cauchy 
distribution 
ga_cauchy_beta 1.0                   # Beta parameter Cauchy 
distribution 
set_ga                               # set the above parameters 
for GA or LGA 
sw_max_its 300                       # iterations of Solis & Wets 
local search 
sw_max_succ 4                        # consecutive successes 
before changing rho 
sw_max_fail 4                        # consecutive failures 
before changing rho 
sw_rho 1.0                           # size of local search space 
to sample 
sw_lb_rho 0.01                       # lower bound on rho 
ls_search_freq 0.06                  # probability of performing 
local search on individual 
set_psw1                             # set the above pseudo-Solis 
& Wets parameters 
unbound_model bound                  # state of unbound ligand 
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ga_run 100                            # do this many hybrid GA-LS 
runs 
analysis                             # perform a ranked cluster 
analysis 
 
Vina Configuration File 
receptor = 4jrg_rec.pdbqt 
ligand = 4jrg_lig.pdbqt 
 
out = out.4jrg.pdbqt 
 
center_x = 11.493 
center_y = 10.5 
center_z = 2.759 
 
size_x = 27 
size_y = 27 
size_z = 27 
 
exhaustiveness = 12 
            
Ligand Input File 
REMARK  6 active torsions: 
REMARK  status: ('A' for Active; 'I' for Inactive) 
REMARK       I    between atoms: C1_1  and  C10_2  
REMARK       I    between atoms: C10_2  and  N11_3  
REMARK       I    between atoms: N11_3  and  C12_4  
REMARK       I    between atoms: C12_4  and  C13_5  
REMARK       I    between atoms: C13_5  and  C14_6  
REMARK    1  A    between atoms: C14_6  and  O14_37  
REMARK    2  A    between atoms: C14_6  and  C15_7  
REMARK    3  A    between atoms: C15_7  and  O15_39  
REMARK    4  A    between atoms: C2_10  and  C21_19  
REMARK    5  A    between atoms: C3_11  and  C31_26  
REMARK       I    between atoms: C4_14  and  C41_15  
REMARK    6  A    between atoms: C41_15  and  C42_33  
ROOT 
ATOM      1  C1  I09 A          11.781  10.738  -1.043  0.00  
0.00     0.159 C  
ATOM      2  C10 I09 A          12.414  11.957  -0.431  0.00  
0.00     0.260 C  
ATOM      3  N11 I09 A          11.556  12.817   0.220  0.00  
0.00    -0.311 N  
ATOM      4  C12 I09 A          12.033  14.023   0.890  0.00  
0.00     0.107 C  
ATOM      5  C13 I09 A          12.241  15.149  -0.123  0.00  
0.00     0.053 C  
ATOM      6  C14 I09 A          12.646  16.423   0.616  0.00  
0.00     0.141 C  
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ATOM      7  O10 I09 A          13.634  12.192  -0.479  0.00  
0.00    -0.271 OA 
ATOM      8  N1  I09 A          10.350  10.632  -0.589  0.00  
0.00     0.252 N  
ATOM      9  C2  I09 A          12.467   9.466  -0.549  0.00  
0.00     0.107 C  
ATOM     10  C3  I09 A          11.330   8.456  -0.438  0.00  
0.00     0.136 C  
ATOM     11  C37 I09 A          10.965   7.977  -1.780  0.00  
0.00     0.081 C  
ATOM     12  N37 I09 A          10.689   7.604  -2.820  0.00  
0.00    -0.197 NA 
ATOM     13  C4  I09 A          10.187   9.303   0.095  0.00  
0.00     0.087 C  
ATOM     14  C41 I09 A           8.816   8.670  -0.208  0.00  
0.00     0.062 C  
ATOM     15  H11 I09 A          10.568  12.607   0.234  0.00  
0.00     0.150 HD 
ATOM     16 2HN1 I09 A          10.137  11.380   0.056  0.00  
0.00     0.199 HD 
ATOM     17 3HN1 I09 A           9.733  10.684  -1.387  0.00  
0.00     0.199 HD 
ENDROOT 
BRANCH   9  18 
ATOM     18  C21 I09 A          13.595   9.007  -1.435  0.00  
0.00    -0.035 A  
ATOM     19  C22 I09 A          14.630   8.269  -0.877  0.00  
0.00     0.024 A  
ATOM     20  C23 I09 A          15.669   7.801  -1.685  0.00  
0.00     0.041 A  
ATOM     21 CL2  I09 A          16.985   6.894  -0.955  0.00  
0.00    -0.084 Cl 
ATOM     22  C24 I09 A          15.678   8.063  -3.063  0.00  
0.00     0.020 A  
ATOM     23  C25 I09 A          14.641   8.817  -3.613  0.00  
0.00     0.002 A  
ATOM     24  C26 I09 A          13.601   9.292  -2.802  0.00  
0.00     0.004 A  
ENDBRANCH   9  18 
BRANCH  10  25 
ATOM     25  C31 I09 A          11.662   7.293   0.469  0.00  
0.00    -0.021 A  
ATOM     26  C36 I09 A          11.426   5.988   0.024  0.00  
0.00     0.007 A  
ATOM     27  C35 I09 A          11.742   4.901   0.841  0.00  
0.00     0.021 A  
ATOM     28  C34 I09 A          12.299   5.122   2.104  0.00  
0.00     0.041 A  
ATOM     29  C33 I09 A          12.538   6.429   2.561  0.00  
0.00     0.021 A  
ATOM     30 CL3  I09 A          12.718   3.745   3.119  0.00  
0.00    -0.084 Cl 
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ATOM     31  C32 I09 A          12.218   7.516   1.745  0.00  
0.00     0.007 A  
ENDBRANCH  10  25 
BRANCH  14  32 
ATOM     32  C42 I09 A           7.720   9.186   0.758  0.00  
0.00    -0.033 C  
ATOM     33  C43 I09 A           6.336   8.796   0.210  0.00  
0.00     0.011 C  
ATOM     34  C44 I09 A           7.901   8.544   2.142  0.00  
0.00     0.011 C  
ATOM     35  C45 I09 A           7.803  10.724   0.897  0.00  
0.00     0.011 C  
ENDBRANCH  14  32 
BRANCH   6  36 
ATOM     36  O14 I09 A          11.500  17.054   1.182  0.00  
0.00    -0.391 OA 
ATOM     37 14HO I09 A          10.882  17.281   0.483  0.00  
0.00     0.211 HD 
ENDBRANCH   6  36 
BRANCH   6  38 
ATOM     38  C15 I09 A          13.403  17.385  -0.310  0.00  
0.00     0.187 C  
BRANCH  38  39 
ATOM     39  O15 I09 A          12.564  17.825  -1.369  0.00  
0.00    -0.394 OA 
ATOM     40 15HO I09 A          13.053  18.425  -1.937  0.00  
0.00     0.210 HD 
ENDBRANCH  38  39 
ENDBRANCH   6  38 
TORSDOF 11 
 
Flexible Residue File 
BEGIN_RES HIS A  69 
REMARK  2 active torsions: 
REMARK  status: ('A' for Active; 'I' for Inactive) 
REMARK    1  A    between atoms: CA   and  CB   
REMARK    2  A    between atoms: CB   and  CG   
ROOT 
ATOM      1  CA  HIS A  69      10.614  13.888   7.010  0.70 
35.51     0.182 C  
ENDROOT 
BRANCH   1   2 
ATOM      2  CB  HIS A  69      11.813  14.799   6.727  0.70 
36.82     0.095 C  
BRANCH   2   3 
ATOM      3  CG  HIS A  69      12.379  15.449   7.950  0.70 
38.82     0.053 A  
ATOM      4  ND1 HIS A  69      13.531  15.004   8.564  0.70 
39.45    -0.247 NA 
ATOM      5  CE1 HIS A  69      13.801  15.779   9.601  0.70 
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38.18     0.207 A  
ATOM      6  NE2 HIS A  69      12.868  16.707   9.684  0.70 
38.06    -0.359 N  
ATOM      7  HE2 HIS A  69      12.824  17.434  10.384  0.70  
0.00     0.166 HD 
ATOM      8  CD2 HIS A  69      11.965  16.525   8.665  0.70 
37.74     0.116 A  
ENDBRANCH   2   3 
ENDBRANCH   1   2 
END_RES HIS A  69 
BEGIN_RES ILE A  57 
REMARK  2 active torsions: 
REMARK  status: ('A' for Active; 'I' for Inactive) 
REMARK    3  A    between atoms: CA   and  CB   
REMARK    4  A    between atoms: CB   and  CG1  
ROOT 
ATOM      9  CA  ILE A  57       5.611   4.348   4.893  1.00 
31.92     0.180 C  
ENDROOT 
BRANCH   9  10 
ATOM     10  CB  ILE A  57       6.798   5.276   4.579  1.00 
30.37     0.013 C  
ATOM     11  CG2 ILE A  57       6.745   6.518   5.452  1.00 
32.04     0.012 C  
BRANCH  10  12 
ATOM     12  CG1 ILE A  57       8.107   4.518   4.810  1.00 
32.69     0.002 C  
ATOM     13  CD1 ILE A  57       9.258   5.022   3.961  1.00 
30.75     0.005 C  
ENDBRANCH  10  12 
ENDBRANCH   9  10 
END_RES ILE A  57 
BEGIN_RES LEU A  50 
REMARK  2 active torsions: 
REMARK  status: ('A' for Active; 'I' for Inactive) 
REMARK    5  A    between atoms: CA   and  CB   
REMARK    6  A    between atoms: CB   and  CG   
ROOT 
ATOM     14  CA  LEU A  50      12.169   2.858  -2.898  1.00 
29.74     0.177 C  
ENDROOT 
BRANCH  14  15 
ATOM     15  CB  LEU A  50      13.101   3.947  -3.433  1.00 
28.76     0.038 C  
BRANCH  15  16 
ATOM     16  CG  LEU A  50      14.583   3.735  -3.102  1.00 
30.22    -0.020 C  
ATOM     17  CD1 LEU A  50      15.429   4.648  -3.971  1.00 
30.37     0.009 C  
ATOM     18  CD2 LEU A  50      14.833   4.003  -1.629  1.00 
24.61     0.009 C  
ENDBRANCH  15  16 
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ENDBRANCH  14  15 
END_RES LEU A  50 
 
Grid Parameter File 
npts 60 62 62                     # num.grid points in xyz 
gridfld 4jrg_rigid.maps.fld          # grid_data_file 
spacing 0.375                        # spacing(A) 
receptor_types A C NA OA N SA HD     # receptor atom types 
ligand_types A C Cl NA OA N HD       # ligand atom types 
receptor 4jrg_rigid.pdbqt            # macromolecule 
gridcenter 11.493 10.5 2.759        # xyz-coordinates or auto 
smooth 0.5                           # store minimum energy w/in 
rad(A) 
map 4jrg_rigid.A.map                 # atom-specific affinity map 
map 4jrg_rigid.C.map                 # atom-specific affinity map 
map 4jrg_rigid.Cl.map                # atom-specific affinity map 
map 4jrg_rigid.NA.map                # atom-specific affinity map 
map 4jrg_rigid.OA.map                # atom-specific affinity map 
map 4jrg_rigid.N.map                 # atom-specific affinity map 
map 4jrg_rigid.HD.map                # atom-specific affinity map 
elecmap 4jrg_rigid.e.map             # electrostatic potential 
map 
dsolvmap 4jrg_rigid.d.map              # desolvation potential 
map 
dielectric -0.1465                   # <0, AD4 distance-
dep.diel;>0, constant 
 
Docking Parameter File 
autodock_parameter_version 4.2       # used by autodock to 
validate parameter set 
outlev 1                             # diagnostic output level 
intelec                              # calculate internal 
electrostatics 
seed pid time                        # seeds for random generator 
ligand_types A C Cl NA OA N HD       # atoms types in ligand 
fld 4jrg_rigid.maps.fld              # grid_data_file 
map 4jrg_rigid.A.map                 # atom-specific affinity map 
map 4jrg_rigid.C.map                 # atom-specific affinity map 
map 4jrg_rigid.Cl.map                # atom-specific affinity map 
map 4jrg_rigid.NA.map                # atom-specific affinity map 
map 4jrg_rigid.OA.map                # atom-specific affinity map 
map 4jrg_rigid.N.map                 # atom-specific affinity map 
map 4jrg_rigid.HD.map                # atom-specific affinity map 
elecmap 4jrg_rigid.e.map             # electrostatics map 
desolvmap 4jrg_rigid.d.map           # desolvation map 
move 4jrg_lig.pdbqt                  # small molecule 
flexres 4jrg_flex.pdbqt                  # file containing 
flexible residues 
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about 11.8028 10.3609 -0.2312        # small molecule center 
tran0 random                         # initial coordinates/A or 
random 
quaternion0 random                   # initial orientation 
dihe0 random                         # initial dihedrals 
(relative) or random 
torsdof 11                            # torsional degrees of 
freedom 
rmstol 2.0                           # cluster_tolerance/A 
extnrg 1000.0                        # external grid energy 
e0max 0.0 10000                      # max initial energy; max 
number of retries 
ga_pop_size 150                      # number of individuals in 
population 
ga_num_evals 20000000                 # maximum number of energy  
evaluations 
ga_num_generations 27000             # maximum number of 
generations 
ga_elitism 1                         # number of top individuals 
to survive to next generation 
ga_mutation_rate 0.02                # rate of gene mutation 
ga_crossover_rate 0.8                # rate of crossover 
ga_window_size 10                    #  
ga_cauchy_alpha 0.0                  # Alpha parameter of Cauchy 
distribution 
ga_cauchy_beta 1.0                   # Beta parameter Cauchy 
distribution 
set_ga                               # set the above parameters 
for GA or LGA 
sw_max_its 300                       # iterations of Solis & Wets 
local search 
sw_max_succ 4                        # consecutive successes 
before changing rho 
sw_max_fail 4                        # consecutive failures 
before changing rho 
sw_rho 1.0                           # size of local search space 
to sample 
sw_lb_rho 0.01                       # lower bound on rho 
ls_search_freq 0.06                  # probability of performing 
local search on individual 
set_psw1                             # set the above pseudo-Solis 
& Wets parameters 
unbound_model bound                  # state of unbound ligand 
ga_run 100                   # do this many hybrid GA-LS runs 
analysis                             # perform a ranked cluster 
analysis 
 
Vina Configuration File 
receptor = 4jrg_rigid.pdbqt 
flex = 4jrg_flex.pdbqt 
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ligand = 4jrg_lig.pdbqt 
 
out = out.4jrg.pdbqt 
 
center_x = 11.493 
center_y = 10.5 
center_z = 2.759 
 
size_x = 27 
size_y = 27 
size_z = 27 
 
exhaustiveness = 12 
 
Appendix B 
 
            NAMD Configuration File: 4ipf 
############################################################# 
## JOB DESCRIPTION                                         ## 
############################################################# 
 
# Minimization and Equilibration of  
# MDM2 in a Water Sphere 
 
 
############################################################# 
## ADJUSTABLE PARAMETERS                                   ## 
############################################################# 
 
structure          4ipf_ws.psf 
coordinates        4ipf_ws.pdb 
 
set temperature    310 
set outputname     4ipf_ws_eq 
 
firsttimestep      0 
 
 
############################################################# 
## SIMULATION PARAMETERS                                   ## 
############################################################# 
 
# Input 
paraTypeCharmm     on 
parameters          par_all27_prot_lipid.inp  
temperature         $temperature 
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# Force-Field Parameters 
exclude             scaled1-4 
1-4scaling          1.0 
cutoff              12.0 
switching           on 
switchdist          10.0 
pairlistdist        14.0 
 
 
# Integrator Parameters 
timestep            1.0  ;# 1fs/step 
rigidBonds          all  ;# needed for 2fs steps 
nonbondedFreq       1 
fullElectFrequency  2   
stepspercycle       10 
 
 
# Constant Temperature Control 
langevin            on    ;# do langevin dynamics 
langevinDamping     1     ;# damping coefficient (gamma) of 1/ps 
langevinTemp        $temperature 
langevinHydrogen    off    ;# don't couple langevin bath to 
hydrogens 
 
 
# Output 
outputName          $outputname 
 
restartfreq         500     ;# 500steps = every 1ps 
dcdfreq             250 
outputEnergies      100 
outputPressure      100 
 
 
############################################################# 
## EXTRA PARAMETERS                                        ## 
############################################################# 
 
# Spherical boundary conditions 
sphericalBC         on 
sphericalBCcenter   30.3081743413, 28.8049907121, 15.353994423 
sphericalBCr1       26.0 
sphericalBCk1       10 
sphericalBCexp1     2 
 
 
############################################################# 
## EXECUTION SCRIPT                                        ## 
############################################################# 
 
# Minimization 
minimize            100 
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reinitvels          $temperature 
 
run 5000000 ;# .5 ns 
 
NAMD PGN File 
package require psfgen 
topology top_all27_prot_lipid.inp 
pdbalias residue HIS HSE 
segment U {pdb 4ipfp.pdb} 
coordpdb 4ipfp.pdb U 
guesscoord 
writepdb 4ipf.pdb 
writepsf 4ipf.psf 
 
 
NAMD Script for Water Sphere 
 
### Script to immerse MDM2 in a sphere of water just large enough  
### to cover it 
 
set molname 4ipf 
 
mol new ${molname}.psf 
mol addfile ${molname}.pdb 
 
### Determine the center of mass of the molecule and store the 
coordinates 
set cen [measure center [atomselect top all] weight mass] 
set x1 [lindex $cen 0] 
set y1 [lindex $cen 1] 
set z1 [lindex $cen 2] 
set max 0 
 
### Determine the distance of the farthest atom from the center 
of mass 
foreach atom [[atomselect top all] get index] { 
  set pos [lindex [[atomselect top "index $atom"] get {x y z}] 0] 
  set x2 [lindex $pos 0] 
  set y2 [lindex $pos 1] 
  set z2 [lindex $pos 2] 
  set dist [expr pow(($x2-$x1)*($x2-$x1) + ($y2-$y1)*($y2-$y1) + 
($z2-$z1)*($z2-$z1),0.5)] 
  if {$dist > $max} {set max $dist} 
  } 
 
mol delete top 
 
### Solvate the molecule in a water box with enough padding (15 
A). 
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### One could alternatively align the molecule such that the 
vector  
### from the center of mass to the farthest atom is aligned with 
an axis, 
### and then use no padding 
package require solvate 
solvate ${molname}.psf ${molname}.pdb -t 20 -o del_water 
 
resetpsf 
package require psfgen 
mol new del_water.psf 
mol addfile del_water.pdb 
readpsf del_water.psf 
coordpdb del_water.pdb 
 
### Determine which water molecules need to be deleted and use a 
for loop 
### to delete them 
set wat [atomselect top "same residue as {water and ((x-$x1)*(x-
$x1) + (y-$y1)*(y-$y1) + (z-$z1)*(z-$z1))<($max*$max)}"] 
set del [atomselect top "water and not same residue as {water and 
((x-$x1)*(x-$x1) + (y-$y1)*(y-$y1) + (z-$z1)*(z-
$z1))<($max*$max)}"] 
set seg [$del get segid] 
set res [$del get resid] 
set name [$del get name] 
for {set i 0} {$i < [llength $seg]} {incr i} { 
  delatom [lindex $seg $i] [lindex $res $i] [lindex $name $i]  
  } 
writepsf ${molname}_ws.psf 
writepdb ${molname}_ws.pdb 
 
mol delete top 
 
mol new ${molname}_ws.psf 
mol addfile ${molname}_ws.pdb 
puts "CENTER OF MASS OF SPHERE IS: [measure center [atomselect 
top all] weight mass]" 
puts "RADIUS OF SPHERE IS: $max" 
mol delete top 
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Appendix C 
 
            Rama Plot 3lbk (0,12)  
 
 
 
 
 
 
            
            
 
 
 
Evaluation of residues 
Residue [A  72 :GLN] (  56.75, -30.86) in Allowed region 
Number of residues in favored region    (~98.0% expected)  :   69 ( 98.6%) 
Number of residues in allowed region     ( ~2.0% expected)  :    1 (  1.4%) 
Number of residues in outlier region                        :    0 (  0.0%) 
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Appendix D 
 
            Rama Plot 4jrg (6,6)
 
 
 
 
 
 
 
Evaluation of residues 
Residue [A  73 :CYS] (-142.26,  20.56) in Allowed region 
Number of residues in favoured region    (~98.0% expected)  :   72 ( 98.6%) 
Number of residues in allowed region     ( ~2.0% expected)  :    1 (  1.4%) 
Number of residues in outlier region                        :    0 (  0.0%) 
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Appendix E          
 
            Rama Plot 4zyi (0,12) 
 
 
 
 
 
Evaluation of residues 
Number of residues in favoured region    (~98.0% expected)  :   77 (100.0%) 
Number of residues in allowed region     ( ~2.0% expected)  :    0 (  0.0%) 
Number of residues in outlier region                        :    0 (  0.0%) 
